82640-04-8 | 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol hydrochloride

Packsize	Purity	Availability	Price	Discounted Price
1g	97%	in stock	$39.00	$27.00
5g	97%	in stock	$122.00	$85.00
10g	97%	in stock	$212.00	$148.00
25g	97%	in stock	$425.00	$297.00
100g	97%	in stock	$1,368.00	$958.00

Description

• Catalog Number: AB53104
• Chemical Name: 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol hydrochloride
• CAS Number: 82640-04-8
• Molecular Formula: C28H28ClNO4S
• Molecular Weight: 510.0442
• MDL Number: MFCD01938233
• SMILES: Oc1ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O.Cl

Computed Properties

• Complexity: 655
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 35
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 7

Literature

• Embryoid body test with morphological and molecular endpoints implicates potential developmental toxicity of trans-resveratrol.

  Toxicology and applied pharmacology 20180915

• Transcriptomic and phenotypic profiling in developing zebrafish exposed to thyroid hormone receptor agonists.

  Reproductive toxicology (Elmsford, N.Y.) 20180401

• Glucuronidation of mono(2-ethylhexyl) phthalate in humans: roles of hepatic and intestinal UDP-glucuronosyltransferases.

  Archives of toxicology 20170201

• Neonatal exposure to SERMs disrupts neuroendocrine development and postnatal reproductive function through alteration of hypothalamic kisspeptin neurons in female rats.

  Neurotoxicology 20160901

• Parabens and Human Epidermal Growth Factor Receptor Ligand Cross-Talk in Breast Cancer Cells.

  Environmental health perspectives 20160501

• Moving Toward Integrating Gene Expression Profiling Into High-Throughput Testing: A Gene Expression Biomarker Accurately Predicts Estrogen Receptor α Modulation in a Microarray Compendium.

  Toxicological sciences : an official journal of the Society of Toxicology 20160501

• Estrogen-responsive genes encoding egg yolk proteins vitellogenin and apolipoprotein II in chicken are differentially regulated by selective estrogen receptor modulators.

  Theriogenology 20160201

• A transgenic mouse model expressing an ERα folding biosensor reveals the effects of Bisphenol A on estrogen receptor signaling.

  Scientific reports 20160101

• Quality of life in Japanese women with postmenopausal osteoporosis treated with raloxifene and vitamin D: post hoc analysis of a postmarketing study.

  Current medical research and opinion 20150101

• Selectivity of natural, synthetic and environmental estrogens for zebrafish estrogen receptors.

  Toxicology and applied pharmacology 20141001

• Mechanism of raloxifene-induced upregulation of glutamate transporters in rat primary astrocytes.

  Glia 20140801

• Profiling of the Tox21 10K compound library for agonists and antagonists of the estrogen receptor alpha signaling pathway.

  Scientific reports 20140101

• Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry.

  Chemical research in toxicology 20130617

• The effect of estrogen compounds on human embryoid bodies.

  Reproductive sciences (Thousand Oaks, Calif.) 20130601

• Electrochemistry of raloxifene on glassy carbon electrode and its determination in pharmaceutical formulations and human plasma.

  Bioelectrochemistry (Amsterdam, Netherlands) 20121201

• The evolution of selective estrogen receptor modulators in osteoporosis therapy.

  Climacteric : the journal of the International Menopause Society 20121201

• Preventive therapy for breast cancer.

  Current oncology reports 20121201

• Cytochrome p450 architecture and cysteine nucleophile placement impact raloxifene-mediated mechanism-based inactivation.

  Molecular pharmacology 20121101

• Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.

  The Cochrane database of systematic reviews 20121017

• The effects of conjugated estrogen, raloxifene and soy extract on collagen in rat bones.

  Climacteric : the journal of the International Menopause Society 20121001

• Influence of hepatic and intestinal efflux transporters and their genetic variants on the pharmacokinetics and pharmacodynamics of raloxifene in osteoporosis treatment.

  Translational research : the journal of laboratory and clinical medicine 20121001

• Mechanisms of the hepatoprotective effects of tamoxifen against drug-induced and chemical-induced acute liver injuries.

  Toxicology and applied pharmacology 20121001

• Methanol extract of dried exudate of Commiphora mukul prevents bone resorption in ovariectomized rats.

  Pharmaceutical biology 20121001

• Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery.

  Xenobiotica; the fate of foreign compounds in biological systems 20120901

• Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series.

  Journal of bone and mineral metabolism 20120901

• The role of aldehyde oxidase and xanthine oxidase in the biotransformation of a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5.

  Drug metabolism and disposition: the biological fate of chemicals 20120901

• Raloxifene attenuates Pseudomonas aeruginosa pyocyanin production and virulence.

  International journal of antimicrobial agents 20120901

• What happened to WHI: menopausal hormonal therapy in 2012.

  Clinical obstetrics and gynecology 20120901

• Exemestane for primary prevention of breast cancer in postmenopausal women.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120815

• Synthesis of aryl ethers via a sulfonyl transfer reaction.

  Organic letters 20120803

• Chemoprevention for breast cancer.

  Cancer treatment reviews 20120801

• Free radical metabolism of raloxifene in human liver microsomes.

  Xenobiotica; the fate of foreign compounds in biological systems 20120801

• Estrogen provokes the depressant effect of chronic nicotine on vagally mediated reflex chronotropism in female rats.

  The Journal of pharmacology and experimental therapeutics 20120801

• Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial.

  European journal of clinical nutrition 20120801

• Effects of estrogen on vascular inflammation: a matter of timing.

  Arteriosclerosis, thrombosis, and vascular biology 20120801

• Correlation between a bone resorption marker and structural geometry of the proximal femur in osteoporotic women treated with raloxifene.

  Journal of orthopaedic surgery (Hong Kong) 20120801

• A nucleotide-gated molecular pore selects sulfotransferase substrates.

  Biochemistry 20120717

• Post-menopausal women with rheumatoid arthritis who are treated with raloxifene or alendronate or glucocorticoids have lower serum undercarboxylated osteocalcin levels.

  Journal of endocrinological investigation 20120701

• A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women.

  Thrombosis research 20120701

• Estrogen receptor β potentiates the antiproliferative effect of raloxifene and affects the cell migration and invasion in HCT-116 colon cancer cells.

  Journal of cancer research and clinical oncology 20120701

• The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.

  Molecular and cellular biochemistry 20120701

• Estrogens plus raloxifene on endometrial safety and menopausal symptoms--semisystematic review.

  Menopause (New York, N.Y.) 20120701

• Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.

  Breast cancer research and treatment 20120701

• Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland.

  Breast cancer research and treatment 20120701

• The effect of raloxifene on Bax protein expression in breast carcinomas of postmenopausal women.

  Diagnostic cytopathology 20120701

• Application of 4D-QSAR studies to a series of raloxifene analogs and design of potential selective estrogen receptor modulators.

  Molecules (Basel, Switzerland) 20120615

• Gonadotrophin receptor hormone analogues in combination with add-back therapy: an update.

  Menopause international 20120601

• A selective estrogen receptor modulator inhibits tumor necrosis factor-α-induced apoptosis through the ERK1/2 signaling pathway in human chondrocytes.

  Biochemical and biophysical research communications 20120511

• Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.

  Journal of bone and mineral metabolism 20120501

• Recent advances in the synthesis of raloxifene: a selective estrogen receptor modulator.

  European journal of medicinal chemistry 20120501

• A multiplexed screening method for agonists and antagonists of the estrogen receptor protein.

  Analytical and bioanalytical chemistry 20120501

• In vitro bioactivation of bazedoxifene and 2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol in human liver microsomes.

  Chemico-biological interactions 20120415

• Teriparatide increases the maturation of circulating osteoblast precursors.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120401

• Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120401

• Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.

  Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons 20120401

• Does hormone therapy, tibolone or raloxifene modify VEGF expression in cervical epithelial cells?

  Climacteric : the journal of the International Menopause Society 20120401

• Diesel exhaust particulate extracts inhibit transcription of nuclear respiratory factor-1 and cell viability in human umbilical vein endothelial cells.

  Archives of toxicology 20120401

• Effects of selective estrogen receptor modulators on allocentric working memory performance and on dendritic spines in medial prefrontal cortex pyramidal neurons of ovariectomized rats.

  Hormones and behavior 20120401

• Beneficial effects of add-on raloxifene in schizophrenia.

  Archives of women's mental health 20120401

• Responses of urinary N-telopeptide and renal calcium handling to PTH infusion after treatment with estrogen, raloxifene, and tamoxifen.

  Calcified tissue international 20120401

• Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials.

  Cancer prevention research (Philadelphia, Pa.) 20120401

• Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.

  The Journal of clinical endocrinology and metabolism 20120401

• Hypocalcemia induced by raloxifene.

  Current drug safety 20120401

• Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120301

• The effect of raloxifene, a SERM, on extracellular matrix protein expression of pelvic fibroblasts.

  International urogynecology journal 20120301

• Effects of administration of hormone therapy or raloxifene on the immune system and on biochemical markers of bone remodeling.

  Menopause (New York, N.Y.) 20120301

• Use of a multistaged time-dependent inhibition assay to assess the impact of intestinal metabolism on drug-drug interaction potential.

  Drug metabolism and disposition: the biological fate of chemicals 20120301

• Differential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women.

  The Journal of clinical endocrinology and metabolism 20120301

• Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy.

  Current osteoporosis reports 20120301

• [Combination or sequential treatment using PTH and anti-resorption therapies].

  Clinical calcium 20120301

• Selective estrogen receptor modulation in pancreatic β-cells and the prevention of type 2 diabetes.

  Islets 20120301

• Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial.

  Journal of the American Medical Directors Association 20120201

• Genistein aglycone, a soy-derived isoflavone, improves skin changes induced by ovariectomy in rats.

  British journal of pharmacology 20120201

• Adiponectin and leptin serum levels in osteoporotic postmenopausal women treated with raloxifene or alendronate.

  Menopause (New York, N.Y.) 20120201

• Raloxifene improves vascular reactivity in pressurized septal coronary arteries of ovariectomized hamsters fed cholesterol diet.

  Pharmacological research 20120201

• Antidepressive and anxiolytic activity of selective estrogen receptor modulators in ovariectomized mice submitted to chronic unpredictable stress.

  Behavioural brain research 20120201

• Breast cancer chemoprevention.

  Expert review of anticancer therapy 20120201

• Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance.

  Oncogene 20120105

• Activation of estrogen receptor α by raloxifene through an activating protein-1-dependent tethering mechanism in human cervical epithelial cancer cells: a role for c-Jun N-terminal kinase.

  Molecular and cellular endocrinology 20120102

• Selective oestrogen receptor modulators decrease the inflammatory response of glial cells.

  Journal of neuroendocrinology 20120101

• Expression of Ki-67 and Bcl-2 biomarkers in normal breast tissue from women of reproductive age treated with raloxifene.

  Archives of gynecology and obstetrics 20120101

• Comparative study of tamoxifen and raloxifene on endometrial cell proliferation of female rats in persistent estrus.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20120101

• Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database.

  Menopause (New York, N.Y.) 20120101

• Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.

  Menopause (New York, N.Y.) 20120101

• Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?

  Calcified tissue international 20120101

• Selective estrogen receptor modulators regulate dendritic spine plasticity in the hippocampus of male rats.

  Neural plasticity 20120101

• The mechanism of vascular calcification - a systematic review.

  Medical science monitor : international medical journal of experimental and clinical research 20120101

• Assessment of micronucleus frequency in the peripheral blood of female rats in persistent estrus treated with selective estrogen receptor modulators.

  Environmental and molecular mutagenesis 20120101

• Evidence to inform decision makers in Thailand: a cost-effectiveness analysis of screening and treatment strategies for postmenopausal osteoporosis.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20120101

• Organic anion transporting polypeptides OATP1B1 and OATP1B3 and their genetic variants influence the pharmacokinetics and pharmacodynamics of raloxifene.

  Journal of translational medicine 20120101

• Effect of raloxifene in human neurocysticercosis.

  BMJ case reports 20120101

• The novel non-steroidal selective androgen receptor modulator S-101479 has additive effects with bisphosphonate, selective estrogen receptor modulator, and parathyroid hormone on the bones of osteoporotic female rats.

  Biological & pharmaceutical bulletin 20120101

• Nanoemulsion liquid preconcentrates for raloxifene hydrochloride: optimization and in vivo appraisal.

  International journal of nanomedicine 20120101

• Selective estrogen receptor modulators and aromatase inhibitors for breast cancer chemoprevention.

  Current drug targets 20111201

• Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).

  American journal of obstetrics and gynecology 20111201

• Raloxifene glucuronidation in human intestine, kidney, and liver microsomes and in human liver microsomes genotyped for the UGT1A1*28 polymorphism.

  Drug metabolism and disposition: the biological fate of chemicals 20111201

• In vitro and in vivo molecular imaging of estrogen receptor α and β homo- and heterodimerization: exploration of new modes of receptor regulation.

  Molecular endocrinology (Baltimore, Md.) 20111201

• What is the significance of gynecologic symptoms in the participants in the NSABP study?

  American journal of obstetrics and gynecology 20111201

• [A case of non-alcoholic fatty liver disease (NAFLD) aggravated after treatment with raloxifene].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20111201

• Non-classical estrogen receptors action on human dermal fibroblasts.

  Taiwanese journal of obstetrics & gynecology 20111201

• Raloxifene inhibits menin-dependent estrogen receptor activation in breast cancer cells.

  Journal of endocrinological investigation 20111201

• Conformational analysis of bivalent estrogen receptor ligands: from intramolecular to intermolecular binding.

  Chembiochem : a European journal of chemical biology 20111125

• Raloxifene protects cultured human chondrocytes from IL-1β induced damage: a biochemical and morphological study.

  European journal of pharmacology 20111116

• The breast cancer chemoprevention debate.

  Journal of the National Cancer Institute 20111116

• Introduction of an electron withdrawing group on the hydroxyphenylnaphthol scaffold improves the potency of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2) inhibitors.

  Journal of medicinal chemistry 20111110

• Raloxifene reduces blood pressure in hypertensive animals after ovarian hormone deprivation.

  Basic & clinical pharmacology & toxicology 20111101

• The effect of raloxifene on telomerase expression in breast carcinoma samples from postmenopausal women.

  European journal of obstetrics, gynecology, and reproductive biology 20111101

• Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20111101

• Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.

  The Journal of clinical psychiatry 20111101

• Raloxifene therapy inhibits osteoclastogenesis during the alveolar healing process in rats.

  Archives of oral biology 20111001

• Osteoporosis screening and treatment guidelines: are they being followed?

  Menopause (New York, N.Y.) 20111001

• Leuprolide acetate depot plus high-dose raloxifene hydrochloride before and after surgery for recurrent vaginal aggressive angiomyxoma: a case report.

  Gynecologic oncology 20111001

• A postmenopausal woman developed a giant endometrial polyp during Raloxifene treatment.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20111001

• Formation of raloxifene homo-dimer in CYP3A4, evidence for multi-substrate binding in a single catalytically competent P450 active site.

  Archives of biochemistry and biophysics 20110915

• Advancement in optimization tactic achieved by newly developed chromatographic response function: application to LC separation of raloxifene and its impurities.

  Talanta 20110915

• Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.

  Journal of bone and mineral metabolism 20110901

• The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.

  The Journal of steroid biochemistry and molecular biology 20110901

• Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene.

  Drug metabolism and disposition: the biological fate of chemicals 20110901

• Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).

  Calcified tissue international 20110901

• Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome.

  Fertility and sterility 20110901

• Long-term raloxifene for postmenopausal osteoporosis.

  Current medical research and opinion 20110901

• Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.

  Clinical therapeutics 20110901

• [Bone and calcium metabolism in patients with rheumatoid arthritis].

  Clinical calcium 20110901

• Chemical genomics profiling of environmental chemical modulation of human nuclear receptors.

  Environmental health perspectives 20110801

• Fourier transform infrared imaging analysis of cancellous bone in alendronate- and raloxifene-treated osteopenic sheep.

  Cells, tissues, organs 20110801

• Determination of raloxifene and its glucuronides in human urine by liquid chromatography-tandem mass spectrometry assay.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110801

• Combination of raloxifene, aspirin and estrogen as novel paradigm of hormone replacement therapy in rabbit model of menopause.

  Acta pharmacologica Sinica 20110801

• Relating pelvic pain location to surgical findings of endometriosis.

  Obstetrics and gynecology 20110801

• Prospective evaluation of Vitamin K2, Raloxifene and their co-administration in osteoporotic rats.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110717

• Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.

  Journal of medicinal chemistry 20110714

• Cinacalcet for the treatment of primary hyperparathyroidism.

  American journal of therapeutics 20110701

• Effects of oestradiol and raloxifene on the induction and effector phases of experimental postmenopausal arthritis and secondary osteoporosis.

  Clinical and experimental immunology 20110701

• [Effects of raloxifene on endothelial function and hemostasis in women with ischemic heart disease].

  Revista espanola de cardiologia 20110701

• [Diagnostic imaging of treatment in osteoporosis: SERM].

  Clinical calcium 20110701

• Serum calcium, phosphorus and cardiovascular events in post-menopausal women.

  International journal of cardiology 20110616

• Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110610

• Breast cancer chemoprevention gets personal.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110610

• Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110601

• Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis.

  Climacteric : the journal of the International Menopause Society 20110601

• Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation.

  Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20110601

• Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.

  Breast cancer research and treatment 20110601

• Effect of oxidative stress on aorta and tibia osteoprotegerin gene expression in ovariectomized rats.

  Minerva endocrinologica 20110601

• Bioadhesive microspheres for bioavailability enhancement of raloxifene hydrochloride: formulation and pharmacokinetic evaluation.

  AAPS PharmSciTech 20110601

• Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies.

  Endocrinology and metabolism clinics of North America 20110601

• Effects of raloxifene on bone mineral metabolism in postmenopausal Japanese women on hemodialysis.

  Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 20110601

• Selective estrogen receptor modulators: the future in menopausal treatment.

  Minerva ginecologica 20110601

• [Selective estrogen receptor modulators: focus on bazedoxifene].

  Minerva ginecologica 20110601

• The effects of selective estrogen receptor modulator treatment following hormone replacement therapy on elderly postmenopausal women with osteoporosis.

  Nitric oxide : biology and chemistry 20110531

• High content imaging-based assay to classify estrogen receptor-α ligands based on defined mechanistic outcomes.

  Gene 20110515

• Breast cancer prevention in high-risk women: searching for new options.

  Journal of the National Cancer Institute 20110504

• Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.

  Journal of cellular physiology 20110501

• Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.

  Annals of the rheumatic diseases 20110501

• Involvement of G-463A MPO gene polymorphism in the response of postmenopausal women to hormone therapy.

  Menopause (New York, N.Y.) 20110501

• Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.

  Menopause (New York, N.Y.) 20110501

• Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure.

  American journal of physiology. Heart and circulatory physiology 20110501

• Preventive therapy for breast cancer: a consensus statement.

  The Lancet. Oncology 20110501

• [Pharmacotherapy of osteoporosis accompanied by lifestyle-related diseases].

  Clinical calcium 20110501

• Real-world challenges of treating osteoporosis.

  The American journal of managed care 20110501

• Stroke in relation to use of raloxifene and other drugs against osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110401

• Adherence and persistence in patients with postmenopausal osteoporosis treated with raloxifene.

  Climacteric : the journal of the International Menopause Society 20110401

• Estrogen receptor ligands counteract cognitive deficits caused by androgen deprivation in male rats.

  Hormones and behavior 20110401

• Design, synthesis, and biological evaluation of imidazolyl derivatives of 4,7-disubstituted coumarins as aromatase inhibitors selective over 17-α-hydroxylase/C17-20 lyase.

  Journal of medicinal chemistry 20110324

• Discovery of novel and potent orally active calcium-sensing receptor antagonists that stimulate pulselike parathyroid hormone secretion: synthesis and structure-activity relationships of tetrahydropyrazolopyrimidine derivatives.

  Journal of medicinal chemistry 20110310

• Adherence to osteoporosis drugs and fracture prevention: no evidence of healthy adherer bias in a frail cohort of seniors.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301

• Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301

• Migraine in women with chronic pelvic pain with and without endometriosis.

  Fertility and sterility 20110301

• Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110301

• Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene.

  Expert opinion on pharmacotherapy 20110301

• Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials.

  International journal of cancer 20110215

• Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake.

  Cancer chemotherapy and pharmacology 20110201

• The effects of native and synthetic estrogenic compounds as well as vitamin D less-calcemic analogs on adipocytes content in rat bone marrow.

  Journal of endocrinological investigation 20110201

• Effects of the combination treatment of raloxifene and alendronate on the biomechanical properties of vertebral bone.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110201

• The inhibitory effect of raloxifene on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells is mediated through a ROS/p38 MAPK/CREB pathway to the up-regulation of heme oxygenase-1 independent of estrogen receptor.

  Biochimie 20110201

• The effects of raloxifene on bone turnover markers and bone mineral density in women on maintenance hemodialysis.

  Clinical and experimental nephrology 20110201

• Selective estrogen receptor modulators as brain therapeutic agents.

  Journal of molecular endocrinology 20110201

• Computational estimation of rainbow trout estrogen receptor binding affinities for environmental estrogens.

  Toxicology and applied pharmacology 20110201

• Effect of raloxifene on arthritis and bone mineral density in rats with collagen-induced arthritis.

  Calcified tissue international 20110201

• Evaluation of estrogen and progesterone receptors in non-neoplastic breast tissue of women of reproductive age exposed to tamoxifen and raloxifene: a randomized, double-blind study.

  Breast cancer research and treatment 20110201

• Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells.

  The Journal of steroid biochemistry and molecular biology 20110201

• The effects of estrogen receptors α- and β-specific agonists and antagonists on cell proliferation and energy metabolism in human bone cell line.

  Journal of cellular biochemistry 20110201

• In-vitro antiproliferative activity of benzopyranone derivatives in comparison with standard chemotherapeutic drugs.

  Archiv der Pharmazie 20110201

• Reduction of stimulated sodium iodide symporter expression by estrogen receptor ligands in breast cancer cells.

  Nuclear medicine and biology 20110201

• Effects of raloxifene on the production of cytokines in stimulated whole blood in ex vivo and in vitro studies.

  The journal of medical investigation : JMI 20110201

• Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis.

  European journal of pharmacology 20110115

• Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids.

  Archives of gynecology and obstetrics 20110101

• Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis.

  Kidney international 20110101

• The gynecologic effects of lasofoxifene, an estrogen agonist/antagonist, in postmenopausal women.

  Menopause (New York, N.Y.) 20110101

• Effects of raloxifene on voltage-dependent T-type Ca2+ channels in mouse spermatogenic cells.

  Pharmacology 20110101

• Prevention of breast cancer: the case for studying inhibition of IGF-1 actions.

  Annals of oncology : official journal of the European Society for Medical Oncology 20110101

• Fibroids (uterine myomatosis, leiomyomas).

  BMJ clinical evidence 20110101

• Cellular mechanisms of acute decrease of glutamate release induced by raloxifene in rat cerebral cortex.

  Neuropharmacology 20110101

• Fracture prevention in postmenopausal women.

  BMJ clinical evidence 20110101

• Estrogens and selective estrogen receptor modulators regulate gene and protein expression in the mesenteric arteries.

  Vascular pharmacology 20110101

• Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis.

  Arthritis research & therapy 20110101

• [Better informed decisions in the management of osteoporosis].

  Reumatologia clinica 20110101

• Exemestane is effective for the chemoprevention of breast cancer.

  CA: a cancer journal for clinicians 20110101

• Effect of Cissus quadrangularis Linn on the development of osteopenia induced by ovariectomy in rats.

  La Clinica terapeutica 20110101

• Effect of raloxifene (a Selective Estrogen Receptor Modulator (SERM)) as coadjuvant to antidepressant treatment: a case report.

  Actas espanolas de psiquiatria 20110101

• Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells.

  PloS one 20110101

• Four decades of discovery in breast cancer research and treatment--an interview with V. Craig Jordan. Interview by Marc Poirot.

  The International journal of developmental biology 20110101

• The effect of long-term hormonal treatment on voiding patterns during filling cystometry and on urethral histology in a postpartum, ovariectomized female rat.

  BJU international 20101201

• Tamoxifen and raloxifene modulate gap junction coupling during early phases of retinoic acid-dependent neuronal differentiation of NTera2/D1 cells.

  Cell biology and toxicology 20101201

• Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men.

  The Journal of clinical endocrinology and metabolism 20101201

• Raloxifene: is it really effective on mood changes in postmenopausal osteopenic women?

  Journal of psychosomatic obstetrics and gynaecology 20101201

• Effects of estrogen, raloxifene, and levormeloxifene on the expression of Rho-kinase signaling molecules in urethral smooth muscle cells.

  Urology 20101201

• Raloxifene temporarily reduces arterial stiffness.

  The journal of obstetrics and gynaecology research 20101201

• Electrocardiograms of menopausal women with coronary heart disease or at increased risk for its occurrence.

  The American journal of cardiology 20101201

• The pharmacokinetics of raloxifene and its interaction with apigenin in rat.

  Molecules (Basel, Switzerland) 20101118

• Tipping the balance for the primary prevention of breast cancer.

  Journal of the National Cancer Institute 20101117

• Third-generation SERMs may face uphill battle.

  Journal of the National Cancer Institute 20101117

• The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation.

  Pharmacological research 20101101

• Identifying cost-effective treatment with raloxifene in postmenopausal women using risk algorithms for fractures and invasive breast cancer.

  Bone 20101101

• Oestrogen-induced epithelial-mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis.

  The Journal of pathology 20101101

• Patient characteristics and utilization of breast cancer screening or diagnostic procedures prior to initiation of raloxifene, bisphosphonates and calcitonin.

  Current medical research and opinion 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis.

  Current medical research and opinion 20101101

• Improved cytochrome P450 3A4 molecular models accurately predict the Phe215 requirement for raloxifene dehydrogenation selectivity.

  Biochemistry 20101019

• Development and validation of a test for environmental estrogens: Checking xeno-estrogen activity by CXCL12 secretion in BREAST CANCER CELL LINES (CXCL-test).

  Environmental toxicology 20101001

• A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX.

  Bone 20101001

• Evista patents upheld.

  Nature reviews. Drug discovery 20101001

• Ductal carcinoma in situ: risk factors and impact of screening.

  Journal of the National Cancer Institute. Monographs 20101001

• Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.

  Journal of the National Cancer Institute. Monographs 20101001

• Adjustment for the measurement error in evaluating biomarkers.

  Statistics in medicine 20100930

• Oestrogens for treatment or prevention of pelvic organ prolapse in postmenopausal women.

  The Cochrane database of systematic reviews 20100908

• Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100901

• Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia.

  Psychoneuroendocrinology 20100901

• Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women with osteoporosis.

  Journal of bone and mineral metabolism 20100901

• Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.

  Asian journal of andrology 20100901

• XbaI polymorphism of the estrogen receptor alpha gene influences the effect of raloxifene on the endothelial function.

  Maturitas 20100901

• In vitro mechanism of action for the cytotoxicity elicited by the combination of epigallocatechin gallate and raloxifene in MDA-MB-231 cells.

  Oncology reports 20100901

• The assessment of estrogenic or anti-estrogenic activity of chemicals by the human stably transfected estrogen sensitive MELN cell line: results of test performance and transferability.

  Reproductive toxicology (Elmsford, N.Y.) 20100801

• Optimization and prevalidation of the in vitro ERalpha CALUX method to test estrogenic and antiestrogenic activity of compounds.

  Reproductive toxicology (Elmsford, N.Y.) 20100801

• Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.

  Current medical research and opinion 20100801

• Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB/W F1 mice.

  The Journal of rheumatology 20100801

• Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.

  International journal of oncology 20100801

• Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.

  Journal of women's health (2002) 20100801

• Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100701

• Analgesic effect of raloxifene on back and knee pain in postmenopausal women with osteoporosis and/or osteoarthritis.

  Journal of bone and mineral metabolism 20100701

• Differential effects of 17beta-estradiol and raloxifene on bone and lipid metabolism in rats with chronic kidney disease and estrogen insufficiency.

  Menopause (New York, N.Y.) 20100701

• Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions.

  Xenobiotica; the fate of foreign compounds in biological systems 20100701

• Persistence to medical treatment of osteoporosis in women at three different clinical settings--a historical cohort study.

  Scandinavian journal of public health 20100701

• Genistein aglycone improves skin repair in an incisional model of wound healing: a comparison with raloxifene and oestradiol in ovariectomized rats.

  British journal of pharmacology 20100701

• Fracture risk in early postmenopausal women assessed using FRAX.

  Joint, bone, spine : revue du rhumatisme 20100701

• Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast.

  Connective tissue research 20100601

• Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.

  Journal of pharmaceutical sciences 20100601

• Particle shape: a new design parameter for passive targeting in splenotropic drug delivery.

  Journal of pharmaceutical sciences 20100601

• Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.

  Journal of controlled release : official journal of the Controlled Release Society 20100601

• Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.

  Cancer prevention research (Philadelphia, Pa.) 20100601

• CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene.

  Biochemistry 20100601

• Radiological reasoning: multiple mesenteric masses.

  AJR. American journal of roentgenology 20100601

• Two good choices to prevent breast cancer: great taste, less filling.

  Cancer prevention research (Philadelphia, Pa.) 20100601

• The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention.

  Cancer prevention research (Philadelphia, Pa.) 20100601

• Long-term follow-up in cancer prevention trials (It ain't over 'til it's over).

  Cancer prevention research (Philadelphia, Pa.) 20100601

• Estrogen and selective estrogen receptor modulators regulate vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in human endometrial stromal cells.

  Fertility and sterility 20100515

• Raloxifene induces nucleolar translocation of the estrogen receptor.

  Molecular and cellular endocrinology 20100505

• Therapeutically relevant concentrations of raloxifene dilate pressurized rat resistance arteries via calcium-dependent endothelial nitric oxide synthase activation.

  Arteriosclerosis, thrombosis, and vascular biology 20100501

• Comparison of the effects of raloxifene and anastrozole on experimental endometriosis.

  European journal of obstetrics, gynecology, and reproductive biology 20100501

• Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women.

  The Journal of clinical endocrinology and metabolism 20100501

• Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.

  Calcified tissue international 20100501

• Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.

  International journal of oncology 20100501

• Effect of Raloxifene on all-cause mortality.

  The American journal of medicine 20100501

• Management of osteoporosis in CKD Stages 3 to 5.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20100501

• [Secondary osteoporosis UPDATE. Bone disease with decreased kidney function].

  Clinical calcium 20100501

• [Secondary osteoporosis UPDATE. Drugs under development for metabolic bone disease].

  Clinical calcium 20100501

• [Secondary osteoporosis UPDATE. Treatment of male osteoporosis. Testosterone replacement therapy etc].

  Clinical calcium 20100501

• Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats.

  Behavioural pharmacology 20100501

• Effects of raloxifene treatment on the phenotype of blood monocytes.

  Canadian journal of physiology and pharmacology 20100501

• My doctor wanted me to start taking Evista (raloxifene hydrochloride) for osteoporosis, but I'm worried because the drug is linked to a risk of blood clots. I have mild hypertension that I manage with medications, diet and exercise. Do you think the drug is safe?

  Heart advisor 20100501

• In the clinic. Breast cancer screening and prevention.

  Annals of internal medicine 20100406

• Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100401

• Contribution of the intra-specimen variations in tissue mineralization to PTH- and raloxifene-induced changes in stiffness of rat vertebrae.

  Bone 20100401

• Osteocalcin immunolabeling during the alveolar healing process in ovariectomized rats treated with estrogen or raloxifene.

  Bone 20100401

• Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences.

  Drug metabolism and disposition: the biological fate of chemicals 20100401

• Selective activation of estrogen receptor-beta target genes by 3,3'-diindolylmethane.

  Endocrinology 20100401

• An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals.

  Molecular endocrinology (Baltimore, Md.) 20100401

• The role of the primary care physician in the prevention, diagnosis and treatment of breast cancer: contemporary knowledge and controversies.

  Southern medical journal 20100401

• Breast cancer: risk assessment and prevention.

  Southern medical journal 20100401

• [Musculoskeletal rehabilitation and bone. Influence of medicines and hormones on musculoskeletal rehabilitation].

  Clinical calcium 20100401

• Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene.

  Cell proliferation 20100401

• The effect of aminoglycoside antibiotics on the thermodynamic properties of liposomal vesicles.

  Journal of liposome research 20100301

• Biodistribution and anticancer activity of a new Vinca alkaloid encapsulated into long-circulating liposomes.

  Journal of liposome research 20100301

• Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women.

  Journal of bone and mineral metabolism 20100301

• The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women.

  Bone 20100301

• Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial.

  Menopause (New York, N.Y.) 20100301

• Cognitive performance test research and clinical perils.

  Menopause (New York, N.Y.) 20100301

• Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.

  Thrombosis and haemostasis 20100301

• Relative effects of tamoxifen, raloxifene, and conjugated equine estrogens on cognition.

  Journal of women's health (2002) 20100301

• [Effects of SERMs on bone health. Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].

  Clinical calcium 20100301

• [Effects of SERMs on bone health. Efficacy of SERM for incidence of fractures in osteoporotic patients with lifestyle-related diseases].

  Clinical calcium 20100301

• [Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events].

  Clinical calcium 20100301

• [Effects of SERMs on bone health. Effects of raloxifene and bisphosphonate on bone quality in osteoporosis: collagen cross-links, mineralization, and bone strength].

  Clinical calcium 20100301

• [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].

  Clinical calcium 20100301

• [Effects of SERMs on bone health. SERM and metabolic markers of bone].

  Clinical calcium 20100301

• [Effects of SERMs on bone health. The potential of SERM in the care of chronic kidney disease-mineral bone and disorders].

  Clinical calcium 20100301

• [Effects of SERMs on bone health. SERM actions other than on the bones. With special reference to the actions of SERM on the skin and vascular elasticity].

  Clinical calcium 20100301

• [Effects of SERMs on bone health. Discrimination of SERMs from bisphosphonates in the treatment of postmenopausal osteoporosis].

  Clinical calcium 20100301

• [Effects of SERMs on bone health. Combination therapy with raloxifene].

  Clinical calcium 20100301

• [Effects of SERMs on bone health. The evaluation of raloxifene treatment for elderly women with osteoporosis using bone turnover markers].

  Clinical calcium 20100301

• Enhanced dissolution and bioavailability of raloxifene hydrochloride by co-grinding with different superdisintegrants.

  Chemical & pharmaceutical bulletin 20100301

• Secondary prevention of osteoporosis in Australia: analysis of government-dispensed prescription data.

  Drugs & aging 20100301

• Effects of raloxifene and estradiol on bone turnover parameters in intact and ovariectomized rats.

  Journal of physiology and biochemistry 20100301

• Another selective estrogen-receptor modulator for osteoporosis.

  The New England journal of medicine 20100225

• FPIN's clinical inquiries. Combination therapy for postmenopausal osteoporosis.

  American family physician 20100215

• Biomechanical and histological outcome of combined raloxifene-estrogen therapy on skeletal and reproductive tissues.

  European journal of pharmacology 20100210

• Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture-healing model at the tibia in rat.

  Langenbeck's archives of surgery 20100201

• Raloxifene and body composition and muscle strength in postmenopausal women: a randomized, double-blind, placebo-controlled trial.

  European journal of endocrinology 20100201

• Gastric and esophagus events before and during treatment of osteoporosis.

  Calcified tissue international 20100201

• Raloxifene decreases serum malondialdehyde and nitric oxide levels in postmenopausal women with end-stage renal disease under chronic hemodialysis therapy.

  The journal of obstetrics and gynaecology research 20100201

• Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism.

  Endocrine 20100201

• Raloxifene enhances spontaneous microaggregation of platelets through upregulation of p44/p42 MAP kinase: a case report.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100101

• Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro.

  Glia 20100101

• Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.

  Menopause (New York, N.Y.) 20100101

• Cardioprotective effects of long-term treatment with raloxifene, a selective estrogen receptor modulator, on myocardial ischemia/reperfusion injury in ovariectomized rats.

  Menopause (New York, N.Y.) 20100101

• In vitro evaluation, biodistribution in rats of radiolabeled raloxifene.

  Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 20100101

• The impact of fewer hip fractures with risedronate versus alendronate in the first year of treatment: modeled German cost-effectiveness analysis.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101

• Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.

  Molecular endocrinology (Baltimore, Md.) 20100101

• Benefits and risks of raloxifene by vertebral fracture status.

  Current medical research and opinion 20100101

• Gene expression profiling studies of three SERMs and their conjugated estrogen combinations in human breast cancer cells: insights into the unique antagonistic effects of bazedoxifene on conjugated estrogens.

  The Journal of steroid biochemistry and molecular biology 20100101

• Histomorphometric analysis and immunolocalization of RANKL and OPG during the alveolar healing process in female ovariectomized rats treated with oestrogen or raloxifene.

  Archives of oral biology 20100101

• Effect of raloxifene on serum lipids for type 2 diabetic menopausal women with or without statin treatment.

  Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20100101

• Expressions of vascular endothelial growth factor and nitric oxide synthase III in the thyroid gland of ovariectomized rats are upregulated by estrogen and selective estrogen receptor modulators.

  Thyroid : official journal of the American Thyroid Association 20100101

• The effects of raloxifene on mammographic breast density: a review of clinical trials.

  Menopause (New York, N.Y.) 20100101

• Effects of raloxifene on the renin-angiotensin-aldosterone system and blood pressure in hypertensive and normotensive osteoporotic postmenopausal women.

  Geriatrics & gerontology international 20100101

• Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.

  Menopause (New York, N.Y.) 20100101

• Effects of raloxifene on brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women.

  International heart journal 20100101

• Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis.

  BMC musculoskeletal disorders 20100101

• Anti-osteoporotic activity of the petroleum ether extract of Cissus quadrangularis Linn. in ovariectomized Wistar rats.

  Chang Gung medical journal 20100101

• Effects of raloxifene on serum macrophage colony-stimulating factor and interleukin-18 levels in postmenopausal women younger than 60 years.

  Menopause (New York, N.Y.) 20100101

• A comparison between bisphosphonates and other treatments for osteoporosis.

  Current pharmaceutical design 20100101

• Performance of quantitative ultrasound measurements of bone for monitoring raloxifene therapy.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20100101

• Raloxifene inhibits tumor growth and lymph node metastasis in a xenograft model of metastatic mammary cancer.

  BMC cancer 20100101

• Role of endogenous and exogenous female sex hormones in arthritis and osteoporosis development in B10.Q-ncf1*/* mice with collagen-induced chronic arthritis.

  BMC musculoskeletal disorders 20100101

• Modulators of androgen and estrogen receptor activity.

  Critical reviews in eukaryotic gene expression 20100101

• Rapid LC-MS drug metabolite profiling using microsomal enzyme bioreactors in a parallel processing format.

  Analytical chemistry 20091215

• Exploration of endocrine-disrupting chemicals on estrogen receptor alpha by the agonist/antagonist differential-docking screening (AADS) method: 4-(1-adamantyl)phenol as a potent endocrine disruptor candidate.

  Toxicology letters 20091201

• In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue.

  The Journal of endocrinology 20091201

• Effects of strontium ranelate, raloxifene and misoprostol on bone mineral density in ovariectomized rats.

  European journal of obstetrics, gynecology, and reproductive biology 20091201

• Raloxifene ameliorates progressive bone loss in postmenopausal dialysis patients with controlled parathyroid hormone levels.

  Clinical nephrology 20091201

• Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.

  Prescrire international 20091201

• Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.

  Annals of internal medicine 20091117

• Effects of raloxifene on cerebral vasospasm after experimental Subarachnoid Hemorrhage in rabbits.

  Surgical neurology 20091101

• The effects of long-term raloxifene and estradiol treatments on bone in a patient with congenital aromatase deficiency.

  Bone 20091101

• Oestradiol and SERM treatments influence oestrogen receptor coregulator gene expression in human skeletal muscle cells.

  Acta physiologica (Oxford, England) 20091101

• Effects of oestrogen agonists on human dermal fibroblasts in an in vitro wounding assay.

  Experimental dermatology 20091101

• Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions.

  The Journal of pharmacology and experimental therapeutics 20091101

• Budget impact analysis of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.

  Japanese journal of clinical oncology 20091101

• Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091101

• Differential estrogen receptor subtype modulators: assessment of estrogen receptor subtype-binding selectivity and transcription-regulating properties of new cycloalkyl pyrazoles.

  The Journal of steroid biochemistry and molecular biology 20091101

• Selective estrogen receptor modulators decrease reactive astrogliosis in the injured brain: effects of aging and prolonged depletion of ovarian hormones.

  Endocrinology 20091101

• Letter by Choi et al regarding article, 'Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors'.

  Circulation 20091027

• Cross-geographic region differences in quality of life in women with and without vertebral fracture.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20091001

• Effects of estradiol benzoate, raloxifen and an ethanolic extract of Cimicifuga racemosa in nonclassical estrogen regulated organs of ovariectomized rats.

  Planta medica 20091001

• Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells.

  Molecular human reproduction 20091001

• Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

  The Journal of clinical endocrinology and metabolism 20091001

• American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

  Gynecologic oncology 20091001

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• Effectiveness of various drug carriers in controlled release formulations of raloxifene HCl prepared by melt mixing.

  Current drug delivery 20091001

• Role of excipients on N-oxide raloxifene generation from raloxifene-excipients binary mixtures.

  Chemical & pharmaceutical bulletin 20091001

• Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.

  Journal of women's health (2002) 20091001

• New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis.

  Breast (Edinburgh, Scotland) 20091001

• A rat model of epilepsy in women: a tool to study physiological interactions between endocrine systems and seizures.

  Endocrinology 20090901

• Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

  Fertility and sterility 20090901

• Breast cancer chemoprevention - a vision not yet realized.

  European journal of cancer care 20090901

• [Therapeutic considerations on secondary osteoporosis caused by diabetes mellitus].

  Clinical calcium 20090901

• The rationale and potential of cancer chemoprevention with special emphasis on breast cancer.

  European journal of cancer (Oxford, England : 1990) 20090901

• Optimized and validated spectrophotometric methods for the determination of raloxifene in pharmaceuticals using permanganate.

  Archives of pharmacal research 20090901

• Raloxifene: its ossification-promoting effect on female mesenchymal stem cells.

  Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association 20090901

• Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10.

  International journal of pharmaceutics 20090813

• The effects of raloxifene hydrochloride on ocular hemodynamics and visual function.

  International ophthalmology 20090801

• Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton.

  Journal of cellular and molecular medicine 20090801

• Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats.

  World journal of urology 20090801

• Effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women.

  Cell proliferation 20090801

• Raloxifene and risk for stroke based on the framingham stroke risk score.

  The American journal of medicine 20090801

• Antitumorigenic effects of tamoxifen, raloxifene and the combination on the development of breast tumors induced by mouse mammary carcinoma cells in balb/c-J female mice.

  Journal of chemotherapy (Florence, Italy) 20090801

• [Biochemical markers of bone turnover. New aspect. Effects of androgen and estrogen on biochemical markers of bone turnover].

  Clinical calcium 20090801

• Effects of different postmenopausal hormone therapy regimens on cerebral blood flow and cognitive functions.

  Advances in therapy 20090801

• Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.

  Maturitas 20090720

• Novel biodegradable polyesters. Synthesis and application as drug carriers for the preparation of raloxifene HCl loaded nanoparticles.

  Molecules (Basel, Switzerland) 20090707

• Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.

  European journal of pharmacology 20090701

• American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090701

• Approaches to osteoporosis: screening and implementing treatment in clinical practice.

  The Journal of family practice 20090701

• Current and emerging therapies for osteoporosis.

  The Journal of family practice 20090701

• Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women.

  Atherosclerosis 20090601

• Ligand diversity of human and chimpanzee CYP3A4: activation of human CYP3A4 by lithocholic acid results from positive selection.

  Drug metabolism and disposition: the biological fate of chemicals 20090601

• Effects of raloxifene on the mammary epithelium of female rats in persistent estrus.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20090601

• Pharmacotherapeutic management of osteoprosis and osteopenia.

  The Nurse practitioner 20090601

• Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.

  The Journal of bone and joint surgery. American volume 20090601

• Ariad's NFkappaB patent claims shot down on appeal.

  Nature biotechnology 20090601

• Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.

  Anti-cancer agents in medicinal chemistry 20090601

• [Effect of raloxifene on fracture healing of rabbits].

  Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery 20090601

• Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis.

  Glia 20090501

• Selective modification of bone quality by PTH, pamidronate, or raloxifene.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20090501

• [Drug selection guide for osteoporosis determined by the clinical staging, pathophysiology and age].

  Nihon rinsho. Japanese journal of clinical medicine 20090501

• [Bone quality].

  Nihon rinsho. Japanese journal of clinical medicine 20090501

• [Bone metabolic marker for osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20090501

• [Evidence for the selective estrogen receptor modulator raloxifene--its pharmacological characteristics, efficacy and safety profiles].

  Nihon rinsho. Japanese journal of clinical medicine 20090501

• [Combination therapy for osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20090501

• [Economics of medicament therapies for osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20090501

• [Breast cancer chemoprevention. Rational, trials results and future].

  Bulletin du cancer 20090501

• [4/5. Osteoporosis].

  Soins; la revue de reference infirmiere 20090501

• Propensity score estimation with missing values using a multiple imputation missingness pattern (MIMP) approach.

  Statistics in medicine 20090430

• More on reports of esophageal cancer with oral bisphosphonate use.

  The New England journal of medicine 20090423

• Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women.

  Archives of gynecology and obstetrics 20090401

• The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia.

  Fertility and sterility 20090401

• Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland.

  Endocrinology 20090401

• Solid state interaction of raloxifene HCl with different hydrophilic carriers during co-grinding and its effect on dissolution rate.

  Drug development and industrial pharmacy 20090401

• Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.

  Bone 20090401

• Comparative methods for analysis of protein covalent modification by electrophilic quinoids formed from xenobiotics.

  Bioconjugate chemistry 20090401

• Effects of UGT1A1*28 polymorphism on raloxifene pharmacokinetics and pharmacodynamics.

  British journal of clinical pharmacology 20090401

• Inhibiting efflux with novel non-ionic surfactants: Rational design based on vitamin E TPGS.

  International journal of pharmaceutics 20090331

• Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk.

  Journal of the National Cancer Institute 20090318

• Effects of zearalenone and alpha-Zearalenol in comparison with Raloxifene on T47D cells.

  Toxicology mechanisms and methods 20090301

• Cell type- and estrogen receptor-subtype specific regulation of selective estrogen receptor modulator regulatory elements.

  Molecular and cellular endocrinology 20090227

• Tamoxifen and raloxifene produce conditioned taste avoidance in female rats: a microstructural analysis of licking patterns.

  Life sciences 20090227

• Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factors.

  Circulation 20090224

• On looking at subgroups.

  Circulation 20090224

• Metabolic inhibition and kinetics of raloxifene by pharmaceutical excipients in human liver microsomes.

  International journal of pharmaceutics 20090223

• Declining breast cancer incidence and decreased HRT use.

  Lancet (London, England) 20090207

• Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090201

• Vitamin D status and response to treatment in post-menopausal osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20090201

• Regulation of the vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells.

  Oncology reports 20090201

• Incidence of invasive breast cancer in postmenopausal women after discontinuation of long-term raloxifene administration.

  Clinical breast cancer 20090201

• Comparative effects of raloxifene, tamoxifen and estradiol on human osteoblasts in vitro: estrogen receptor dependent or independent pathways of raloxifene.

  The Journal of steroid biochemistry and molecular biology 20090201

• Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan.

  British journal of cancer 20090127

• Effects of raloxifene and hormone replacement therapy on forearm skin elasticity in postmenopausal women.

  Maturitas 20090120

• Effect of raloxifene and low-dose percutaneous 17beta-estradiol on menopause symptoms and endometrium--a randomized controlled trial.

  Maturitas 20090120

• Regression of hepatic adenomata after cessation of selective oestrogen receptor modulator.

  Liver international : official journal of the International Association for the Study of the Liver 20090101

• Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease.

  Stroke 20090101

• Effects of raloxifene on Ki-67 and CD34 antigen expression in breast cancer.

  Gynecologic and obstetric investigation 20090101

• Potential use of an estrogen-glucocorticoid receptor chimera as a drug screen for tissue selective estrogenic activity.

  Bone 20090101

• Raloxifene use in clinical practice: efficacy and safety.

  Menopause (New York, N.Y.) 20090101

• The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.

  Expert review of anticancer therapy 20090101

• The levels of glutathione and nitrite-nitrate and the expression of Bcl-2 mRNA in ovariectomized rats treated by raloxifene against kainic acid.

  The International journal of neuroscience 20090101

• Estrogen receptor-beta as a potential target for colon cancer prevention: chemoprevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 rats.

  Cancer prevention research (Philadelphia, Pa.) 20090101

• Two years adherence to anti-osteoporotic medications in postmenopausal Israeli women.

  Archives of gerontology and geriatrics 20090101

• The use of tamoxifen and raloxifene for the prevention of breast cancer.

  Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20090101

• Targeted delivery of insulin-modified immunoliposomes in vivo.

  Journal of liposome research 20090101

• Low-dose transdermal estradiol induces breast density and heterogeneity changes comparable to those of raloxifene.

  Menopause (New York, N.Y.) 20090101

• Raloxifene and stroke risks in Japanese postmenopausal women with osteoporosis on postmarketing surveillance.

  Menopause (New York, N.Y.) 20090101

• A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system.

  Acta biochimica Polonica 20090101

• Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.

  Menopause (New York, N.Y.) 20090101

• The role of pH in the glucuronidation of raloxifene, mycophenolic acid and ezetimibe.

  Molecular pharmaceutics 20090101

• The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis.

  Menopause (New York, N.Y.) 20090101

• Effect of low-dose tacrolimus coadministered with raloxifene on the skeletal system in male rats.

  Acta poloniae pharmaceutica 20090101

• Mean residence time as estimated from cropped and truncated moments.

  Arzneimittel-Forschung 20090101

• Altering the propensity for density: the benefits and risks of selective estrogen receptor modulators.

  Menopause (New York, N.Y.) 20090101

• Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women.

  Climacteric : the journal of the International Menopause Society 20090101

• Estrogenic control of mitochondrial function and biogenesis.

  Journal of cellular biochemistry 20081215

• Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition.

  Archives of toxicology 20081201

• Parathyroid hormone treatment for osteoporosis.

  Current opinion in endocrinology, diabetes, and obesity 20081201

• Five female cases of prolonged depression in chronic anorexia nervosa treated with selective estrogen receptor modulator raloxifene-augmented therapy.

  Journal of clinical psychopharmacology 20081201

• Chemoprevention of breast cancer.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20081201

• Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene.

  Clinical interventions in aging 20081201

• Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats.

  Chemical research in toxicology 20081201

• Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model.

  Atherosclerosis 20081101

• Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol.

  British journal of pharmacology 20081101

• Estrogen directly modulates circadian rhythms of PER2 expression in the uterus.

  American journal of physiology. Endocrinology and metabolism 20081101

• Effects of estrogen, raloxifene and levormeloxifene on alpha1A-adrenergic receptor expression.

  The Journal of urology 20081101

• Development of an early biomarker for the ovarian liability of selective estrogen receptor modulators in rats.

  The Journal of steroid biochemistry and molecular biology 20081101

• Raloxifene effects on thyroid gland morphology in ovariectomized rats.

  Fertility and sterility 20081001

• Raloxifene protects endothelial cell function against oxidative stress.

  British journal of pharmacology 20081001

• Are the serum levels of sCD40L modified by raloxifene in postmenopausal women?

  European journal of obstetrics, gynecology, and reproductive biology 20081001

• Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus.

  Journal of molecular endocrinology 20081001

• Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women.

  Climacteric : the journal of the International Menopause Society 20081001

• Regulation of estrogenic effects by beclin 1 in breast cancer cells.

  Cancer research 20081001

• [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].

  Clinical calcium 20081001

• [Treatment of osteoporosis in the elderly: what is the evidence?].

  Tijdschrift voor gerontologie en geriatrie 20081001

• Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model.

  European journal of pharmacology 20080911

• Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.

  Breast cancer research and treatment 20080901

• Estrogen regulates responses of dopamine neurons in the ventral tegmental area to cocaine.

  Psychopharmacology 20080901

• Association of ovarian and uterine cancers with postmenopausal hormonal treatments.

  Clinical obstetrics and gynecology 20080901

• Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.

  Chemical research in toxicology 20080901

• Treatment of osteoporosis: all the questions we still cannot answer.

  The American journal of medicine 20080901

• Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20080901

• Toward optimal health: advances in breast cancer detection and management. Interview by Jodi R. Godfrey.

  Journal of women's health (2002) 20080901

• Dosing time-dependent effect of raloxifene on plasma fibrinogen concentration in ovariectomized rats.

  Chronobiology international 20080901

• Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells.

  Medical molecular morphology 20080901

• To switch or not to switch: should the study of tamoxifen and raloxifene (STAR) trial alter our decision?

  Taiwanese journal of obstetrics & gynecology 20080901

• [Treatment of osteoporosis in octogenarians].

  Revue medicale de Bruxelles 20080901

• Gradient HPLC analysis of raloxifene hydrochloride and its application to drug quality control.

  Acta pharmaceutica (Zagreb, Croatia) 20080901

• Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080801

• Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080801

• Effect of raloxifene on the vaginal epithelium of postmenopausal women.

  European journal of obstetrics, gynecology, and reproductive biology 20080801

• [Daily practice using the guidelines for prevention and treatment of osteoporosis. Utilization of metabolic markers of bone in daily osteoporosis practice].

  Clinical calcium 20080801

• The endocrine prevention of breast cancer.

  Best practice & research. Clinical endocrinology & metabolism 20080801

• Raloxifene, a selective estrogen receptor modulator, inhibits lipopolysaccharide-induced nitric oxide production by inhibiting the phosphatidylinositol 3-kinase/Akt/nuclear factor-kappa B pathway in RAW264.7 macrophage cells.

  Molecules and cells 20080731

• Raloxifene analogue LY117018 suppresses oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway.

  European journal of pharmacology 20080728

• Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.

  Molecular and cellular endocrinology 20080716

• Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080701

• Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080701

• The effect of raloxifene treatment in postmenopausal women with CKD.

  Journal of the American Society of Nephrology : JASN 20080701

• Selective oestrogen receptor (ER) modulators reduce microglia reactivity in vivo after peripheral inflammation: potential role of microglial ERs.

  The Journal of endocrinology 20080701

• Efficacy of Raloxifen in treatment of fibromyalgia in menopausal women.

  European journal of internal medicine 20080701

• Effect of raloxifene on mammographic density and breast magnetic resonance imaging in premenopausal women at increased risk for breast cancer.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20080701

• [Role of estrogen and selective estrogen receptor modulators in anti-aging].

  Clinical calcium 20080701

• Understanding risk factors, screening, and treatment of postmenopausal osteoporosis.

  Orthopedics 20080701

• Impact of economic, regulatory, and patent policies on innovation in cancer chemoprevention.

  Cancer prevention research (Philadelphia, Pa.) 20080701

• Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.

  Maturitas 20080620

• The rise of raloxifene and the fall of invasive breast cancer.

  Journal of the National Cancer Institute 20080618

• Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.

  Journal of the National Cancer Institute 20080618

• Activity of three selective estrogen receptor modulators on hormone-dependent responses in the mouse uterus and mammary gland.

  Molecular and cellular endocrinology 20080611

• pH control of nucleophilic/electrophilic oxidation.

  International journal of pharmaceutics 20080605

• Review of comparative effectiveness of treatments to prevent fractures.

  Annals of internal medicine 20080603

• Using location, color, size, and depth to characterize and identify endometriosis lesions in a cohort of 133 women.

  Fertility and sterility 20080601

• Comparative effects of 17beta-estradiol, raloxifene and genistein on bone 3D microarchitecture and volumetric bone mineral density in the ovariectomized mice.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080601

• Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080601

• Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial.

  Archives of gynecology and obstetrics 20080601

• Raloxifene can reduce giant cell tumor recurrence: a new adjuvant therapy.

  Annals of surgical oncology 20080601

• Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and raloxifene on C-reactive protein and other inflammatory markers.

  Journal of thrombosis and haemostasis : JTH 20080601

• Long-term anti-arthritic and anti-osteoporotic effects of raloxifene in established experimental postmenopausal polyarthritis.

  Clinical and experimental immunology 20080601

• Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes.

  American journal of physiology. Heart and circulatory physiology 20080601

• [Muscle and bone health as a risk factor of fall among the elderly. Role of raloxifene in the prevention of osteoporotic fractures].

  Clinical calcium 20080601

• Effects of estrogen and estrogenic compounds on cognition in ovariectomized rats.

  Climacteric : the journal of the International Menopause Society 20080601

• Clinical challenges in the management of osteoporosis.

  Clinical interventions in aging 20080601

• Differential effects of ovarian steroids and raloxifene on serotonin 1A and 2C receptor protein expression in macaques.

  Endocrine 20080601

• Summaries for patients. Drug therapy for osteoporosis.

  Annals of internal medicine 20080506

• Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.

  Annals of internal medicine 20080506

• The search for good compliance: economic aspects of a conveyed combination pharmaco-therapy, exemplified by an osteoporosis therapy.

  The European journal of health economics : HEPAC : health economics in prevention and care 20080501

• Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells.

  Breast cancer research and treatment 20080501

• Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate.

  International journal of cancer 20080501

• International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.

  International journal of cancer 20080501

• Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.

  BJOG : an international journal of obstetrics and gynaecology 20080501

• Raloxifene in breast cancer prevention.

  Expert opinion on drug safety 20080501

• Raloxifene has favourable effects on metabolic parameters but has no effect on left ventricular function in postmenopausal women.

  Pharmacological research 20080501

• Gene expression profiles in breast cancer to identify estrogen receptor target genes.

  Mini reviews in medicinal chemistry 20080501

• The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance.

  Frontiers in bioscience : a journal and virtual library 20080501

• Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.

  Journal of endocrinological investigation 20080501

• Preventing breast cancer in high-risk women, 2008.

  Oncology (Williston Park, N.Y.) 20080501

• Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines.

  Oncogene 20080424

• The combination of raloxifene and epigallocatechin gallate suppresses growth and induces apoptosis in MDA-MB-231 cells.

  Life sciences 20080423

• Daidzein but not other phytoestrogens preserves bone architecture in ovariectomized female rats in vivo.

  Journal of cellular biochemistry 20080415

• Interest in breast cancer chemoprevention among older women.

  Breast cancer research and treatment 20080401

• E-cadherin expression in cervical epithelial cells of postmenopausal women: association with hormone therapy, tibolone, and raloxifene.

  Fertility and sterility 20080401

• An evidence-based approach to hormonal therapies for premenopausal women with fibroids.

  Best practice & research. Clinical obstetrics & gynaecology 20080401

• Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080401

• Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20080401

• Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.

  Climacteric : the journal of the International Menopause Society 20080401

• [Expression of Bax protein in normal tissue of premenopausal women treated with raloxifene].

  Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia 20080401

• Effects of raloxifene on insulin sensitivity, beta-cell function, and hepatic insulin extraction in normal postmenopausal women.

  Fertility and sterility 20080301

• Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080301

• Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080301

• Association between baseline values of bone turnover markers and bone mineral density and their response to raloxifene treatment in Japanese postmenopausal women with osteoporosis.

  Endocrine journal 20080301

• Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis.

  Endocrine journal 20080301

• Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.

  Current medical research and opinion 20080301

• [Assessment of bone quality. Bone quality and osteoporosis treatment].

  Clinical calcium 20080301

• [Assessment of bone quality. Effects of bisphosphonates, raloxifene, alfacalcidol, and menatetrenone on bone quality: collagen cross-links, mineralization, and microdamage].

  Clinical calcium 20080301

• Chemoprevention of breast cancer.

  Expert review of anticancer therapy 20080301

• The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.

  Taiwanese journal of obstetrics & gynecology 20080301

• Tamoxifen: to use or not to use.

  Taiwanese journal of obstetrics & gynecology 20080301

• Raloxifene for older women: a review of the literature.

  Clinical interventions in aging 20080301

• [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].

  Vnitrni lekarstvi 20080301

• Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis.

  Yonsei medical journal 20080227

• Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene.

  Molecular endocrinology (Baltimore, Md.) 20080201

• Selective estrogen receptor modulators accelerate cutaneous wound healing in ovariectomized female mice.

  Endocrinology 20080201

• The potential influence of CO2, as an agent for euthanasia, on the pharmacokinetics of basic compounds in rodents.

  Drug metabolism and disposition: the biological fate of chemicals 20080201

• Role of raloxifene on platelet metabolism and plasma lipids.

  European journal of clinical investigation 20080201

• Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.

  Thrombosis and haemostasis 20080201

• [The role of mitogen-activated protein kinase cascades in inhibition of proliferation in human prostate carcinoma cells by raloxifene: an in vitro experiment].

  Zhonghua yi xue za zhi 20080122

• [Long term effects of raloxifen on the bones].

  Ugeskrift for laeger 20080121

• Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene.

  Maturitas 20080120

• Pharmacokinetics of raloxifene in male Wistar-Hannover rats: influence of complexation with hydroxybutenyl-beta-cyclodextrin.

  International journal of pharmaceutics 20080104

• The effects of raloxifen on depression and cognition in ovariectomized rats.

  Fertility and sterility 20080101

• Effects of estradiol and raloxifene on arterial thrombosis in ovariectomized mice.

  Menopause (New York, N.Y.) 20080101

• Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.

  Familial cancer 20080101

• Pharmacophore mapping of arylbenzothiophene derivatives for MCF cell inhibition using classical and 3D space modeling approaches.

  Journal of molecular graphics & modelling 20080101

• Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20080101

• Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20080101

• Hormone modulation: a novel therapeutic approach for women with severe mental illness.

  The Australian and New Zealand journal of psychiatry 20080101

• Tamoxifen: catalyst for the change to targeted therapy.

  European journal of cancer (Oxford, England : 1990) 20080101

• Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial.

  Obstetrics and gynecology 20080101

• Chemoprevention of breast cancer.

  Breast cancer (Tokyo, Japan) 20080101

• Three-month changes in bone turnover markers and bone mineral density response to raloxifene in Japanese postmenopausal women with osteoporosis.

  Journal of bone and mineral metabolism 20080101

• Randomized clinical trials of raloxifene: reducing the risk of osteoporosis and breast cancer in postmenopausal women.

  Menopause (New York, N.Y.) 20080101

• Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.

  Menopause (New York, N.Y.) 20080101

• Prevention of breast cancer using SERMs.

  Advances in experimental medicine and biology 20080101

• [Effect of the raloxifene versus combined hormonal therapy on the mammary density].

  Revista medica del Instituto Mexicano del Seguro Social 20080101

• [Hormone replacement therapy and cardiovascular prevention. Where are we now?].

  Medicina 20080101

• Raloxifene-induced acceleration of platelet aggregation.

  Internal medicine (Tokyo, Japan) 20080101

• Raloxifene: a review of its use in the prevention of invasive breast cancer.

  Drugs 20080101

• Raloxifene plus ossein-hydroxyapatite compound versus raloxifene plus calcium carbonate to control bone loss in postmenopausal women: a randomized trial.

  Menopause (New York, N.Y.) 20080101

• A comparison of hormone therapies on the urinary excretion of prostacyclin and thromboxane A2.

  Climacteric : the journal of the International Menopause Society 20080101

• Effects of raloxifene on the urethra of adult castrated female rats.

  Climacteric : the journal of the International Menopause Society 20080101

• Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates.

  BMC women's health 20080101

• Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071220

• Projecting individualized absolute invasive breast cancer risk in African American women.

  Journal of the National Cancer Institute 20071205

• Gynecologic and hormonal effects of raloxifene in premenopausal women.

  Fertility and sterility 20071201

• Mechanism of the divergent effects of estrogen on the cell proliferation of human umbilical endothelial versus aortic smooth muscle cells.

  Endocrinology 20071201

• Clinical significance of 1-year treatment with raloxifene on bone and lipid metabolism in Japanese postmenopausal women with osteoporosis.

  Endocrine journal 20071201

• Differential time-dependent inactivation of P450 3A4 and P450 3A5 by raloxifene: a key role for C239 in quenching reactive intermediates.

  Chemical research in toxicology 20071201

• Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women.

  Climacteric : the journal of the International Menopause Society 20071201

• Effect of raloxifene on cerebral vasospasm following experimental subarachnoid hemorrhage in rats.

  Neurologia medico-chirurgica 20071201

• The effects of raloxifene and tibolone on homocysteine and vascular histopathological changes.

  Clinical and experimental medicine 20071201

• Breast cancer risk management.

  Clinical breast cancer 20071201

• [Where do SERMs stand in the light of clinical application?].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [First choice drug for treatment of osteoporosis and the strategic points for choice of drugs].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [CORE study].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [Combination therapy for osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [Evidence of raloxifene on postmenopausal osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [Effects of SERM on the cardiovascular system].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [Transplantation and osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20071128

• [Osteoporosis in cancer survivors].

  Medicina clinica 20071110

• A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.

  European journal of obstetrics, gynecology, and reproductive biology 20071101

• Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene.

  Chemical research in toxicology 20071101

• Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.

  Current medical research and opinion 20071101

• Cognitive effects of short-term use of raloxifene: a randomized clinical trial.

  The International journal of neuroscience 20071101

• Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20071101

• Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20071101

• [Adverse events of drugs for the treatment of osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20071028

• Effects of tibolone and raloxifene on health-related quality of life and sexual function.

  Maturitas 20071020

• Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.

  The Cochrane database of systematic reviews 20071017

• Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene.

  ChemMedChem 20071001

• Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry.

  Chemical research in toxicology 20071001

• Effects of hormone treatment on hemostasis variables.

  Climacteric : the journal of the International Menopause Society 20071001

• Osteoporosis: non-hormonal treatment.

  Climacteric : the journal of the International Menopause Society 20071001

• Protective effect of raloxifene on lipopolysaccharide and acid- induced acute lung injury in rats.

  Acta pharmacologica Sinica 20071001

• Role of raloxifene as a potent inhibitor of experimental postmenopausal polyarthritis and osteoporosis.

  Arthritis and rheumatism 20071001

• Modern milk alkali syndrome--a preventable serious condition.

  The New Zealand medical journal 20070921

• Follow-up of patients with early breast cancer.

  The New England journal of medicine 20070906

• SERMs for the treatment and prevention of breast cancer.

  Reviews in endocrine & metabolic disorders 20070901

• Therapeutic concentrations of raloxifene augment nitric oxide-dependent coronary artery dilatation in vitro.

  British journal of pharmacology 20070901

• Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women.

  Calcified tissue international 20070901

• Rapid endometrial preparation for hysteroscopic surgery with oral desogestrel plus vaginal raloxifene: a prospective, randomized pilot study.

  Fertility and sterility 20070901

• Raloxifene examined for breast cancer prevention.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20070901

• [Hormone replacement Up-to-date. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis].

  Clinical calcium 20070901

• Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.

  European cytokine network 20070901

• Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms.

  Molecular cancer therapeutics 20070901

• [Current and future prospects for anti-osteoporotic drugs].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20070901

• The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.

  Journal of the National Comprehensive Cancer Network : JNCCN 20070901

• Resonance Rayleigh scattering spectral method for the determination of raloxifene using gold nanoparticle as a probe.

  Analytica chimica acta 20070829

• Hope for axed cancer-prevention trial.

  Nature 20070823

• Development and validation of a liquid chromatography-tandem mass spectrometry assay for determination of raloxifene and its metabolites in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070815

• The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women.

  Fertility and sterility 20070801

• Raloxifene increases proliferation of human endothelial cells in association with increased gene expression of cyclins A and B1.

  Fertility and sterility 20070801

• Effect of raloxifene -- a selective oestrogen receptor modulator -- on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial.

  Diabetic medicine : a journal of the British Diabetic Association 20070801

• QUS in monitoring raloxifene and estrogen-progestogens: a 4-year longitudinal study.

  Ultrasound in medicine & biology 20070801

• Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone.

  Endocrinology 20070801

• Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells.

  Pharmacological research 20070801

• Raloxifene, tamoxifen and vascular tone.

  Clinical and experimental pharmacology & physiology 20070801

• Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy.

  Nature clinical practice. Endocrinology & metabolism 20070801

• Raloxifene: cardiovascular considerations.

  Mini reviews in medicinal chemistry 20070801

• [Review of pharmacological treatment of the menopause].

  Atencion primaria 20070801

• Effects of hormonal therapy on cognitive functioning in breast cancer patients: a review of the literature.

  Minerva ginecologica 20070801

• Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene.

  Atherosclerosis 20070701

• Multiple transcription factor elements collaborate with estrogen receptor alpha to activate an inducible estrogen response element in the NKG2E gene.

  Endocrinology 20070701

• Hormone therapy and raloxifene reduce the coagulation inhibitor potential.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20070701

• Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20070701

• NCI and the STELLAR trial.

  Lancet (London, England) 20070630

• Raloxifene acutely reduces glutamate-induced intracellular calcium increase in cultured rat cortical neurons via inhibition of high-voltage-activated calcium current.

  Neuroscience 20070629

• [Prevention of hereditary breast cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20070628

• [Current perspective of chemoprevention in breast cancer].

  Nihon rinsho. Japanese journal of clinical medicine 20070628

• Moving forward with breast cancer prevention.

  Cancer 20070615

• Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells.

  Oncogene 20070614

• Raloxifene inhibits transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes.

  European journal of pharmacology 20070601

• Hormonal interventions to prevent hormonal cancers: breast and prostate cancers.

  European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 20070601

• Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.

  British journal of pharmacology 20070601

• The long-term effect of raloxifene on the genitourinary tract.

  Climacteric : the journal of the International Menopause Society 20070601

• Time-dependent inactivation of P450 3A4 by raloxifene: identification of Cys239 as the site of apoprotein alkylation.

  Chemical research in toxicology 20070601

• Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system.

  Thrombosis and haemostasis 20070601

• Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma.

  Urology 20070601

• Raloxifene modulates pulmonary vascular reactivity in spontaneously hypertensive rats.

  Journal of cardiovascular pharmacology 20070601

• Estrogens shield breast cancer cells.

  Environmental health perspectives 20070601

• A reconsideration of tamoxifen use for breast cancer.

  Taiwanese journal of obstetrics & gynecology 20070601

• Primary prevention of breast cancer: new approaches.

  Maturitas 20070520

• Influence of estrogens and antiestrogens on the expression of selected hormone-responsive genes.

  Maturitas 20070520

• Concentration-dependent effects of a selective estrogen receptor modulator raloxifene on proliferation and apoptosis in human uterine leiomyoma cells cultured in vitro.

  Human reproduction (Oxford, England) 20070501

• Regulation of growth hormone signaling by selective estrogen receptor modulators occurs through suppression of protein tyrosine phosphatases.

  Endocrinology 20070501

• Quantifying the treatment effect explained by markers in the presence of measurement error.

  Statistics in medicine 20070430

• Raloxifene plus 17beta-estradiol inhibits proliferation of primary cultured vascular smooth muscle cells and human mammary endothelial cells via the janus kinase/signal transducer and activator of transcription3 cascade.

  European journal of pharmacology 20070430

• Raloxifene blocks estradiol induction of the serotonin transporter and 5-hydroxytryptamine2A receptor in female rat brain.

  Neuroscience letters 20070424

• Selective estrogen receptor modulators (SERMs) for uterine leiomyomas.

  The Cochrane database of systematic reviews 20070418

• [Progress in diagnosis and therapy: Hypercalcemia due to primary hyperparathyroidism].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20070410

• Risk factors for breast cancer in older women: the relative contribution of bone mineral density and other established risk factors.

  Breast cancer research and treatment 20070401

• Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.

  Bone 20070401

• Raloxifene and ICI182,780 increase estrogen receptor-alpha association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12.

  Molecular endocrinology (Baltimore, Md.) 20070401

• The embryonic pregnancy signal oestradiol influences gene expression at the level of translational initiation in porcine endometrial cells.

  Reproduction in domestic animals = Zuchthygiene 20070401

• Exonic, but not intronic polymorphisms of ESR1 gene might influence the hypolipemic effect of raloxifene.

  The Journal of steroid biochemistry and molecular biology 20070401

• U.S. Food and drug administration analysis of strokes associated with raloxifene.

  Obstetrics and gynecology 20070401

• Osteoporosis: pathogenesis, new therapies and surgical implications.

  Clinics in podiatric medicine and surgery 20070401

• Carotid artery intima-media thickness after raloxifene treatment.

  Journal of women's health (2002) 20070401

• Remarkable antidepressant augmentation effect of raloxifene, a selective estrogen receptor modulator, in a partial responder to fluvoxamine: a case report.

  The Journal of clinical psychiatry 20070401

• Osteoporosis drug effective in preventing breast cancer.

  Mayo Clinic health letter (English ed.) 20070401

• Effect of genistein and raloxifene on vascular dependent platelet aggregation.

  Molecular and cellular endocrinology 20070315

• SERMs: meeting the promise of multifunctional medicines.

  Journal of the National Cancer Institute 20070307

• Oestrogens inhibit interleukin 1beta-mediated nitric oxide synthase expression in articular chondrocytes through nuclear factor-kappa B impairment.

  Annals of the rheumatic diseases 20070301

• The antioxidant effect of estrogen and Selective Estrogen Receptor Modulators in the inhibition of osteocyte apoptosis in vitro.

  Bone 20070301

• Apoptosis in raloxifene-treated postmenopausal women.

  Cell biology international 20070301

• The determination of raloxifene in rat tissue using HPLC.

  Biomedical chromatography : BMC 20070301

• Do estrogen or selective estrogen receptor modulators improve quality of life for women with postmenopausal osteoporosis?

  Current osteoporosis reports 20070301

• Bone quality: an empty term.

  PLoS medicine 20070301

• Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.

  The American journal of medicine 20070301

• Nonsurgical management of primary hyperparathyroidism.

  Mayo Clinic proceedings 20070301

• [Prevention of breast cancer 2007. New evidence?].

  Atencion primaria 20070301

• [Recent topics in the treatment of osteoporosis in Japan].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20070301

• Why is the RUTH trial so important?

  Maturitas 20070220

• [Drug prevention and proper nutrition. Prevention of breast cancer as in coronary heart disease?].

  MMW Fortschritte der Medizin 20070215

• Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.

  International journal of oncology 20070201

• Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis.

  Archives of medical research 20070201

• An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults.

  Current medical research and opinion 20070201

• Endothelium-independent relaxation to raloxifene in porcine coronary artery.

  European journal of pharmacology 20070126

• Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women.

  Maturitas 20070120

• Raloxifene vs tamoxifen.

  JAMA 20070117

• Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.

  Thrombosis research 20070101

• Raloxifen prevents bone loss in castrated male mice.

  Physiological research 20070101

• The potential antioxidant effect of raloxifene treatment: a study on heart, liver and brain cortex of ovariectomized female rats.

  Cell biochemistry and function 20070101

• Different effects of raloxifene and estrogen on interleukin-1beta and interleukin-1 receptor antagonist production using in vitro and ex vivo studies.

  Bone 20070101

• Beyond raloxifene for the prevention of osteoporosis and breast cancer.

  British journal of pharmacology 20070101

• Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134).

  British journal of pharmacology 20070101

• Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.

  Menopause (New York, N.Y.) 20070101

• Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.

  Thrombosis research 20070101

• Chemoprevention of breast cancer with selective oestrogen-receptor modulators.

  Nature reviews. Cancer 20070101

• The current status of breast cancer chemoprevention: a star is born.

  Journal of surgical oncology 20070101

• Two unsuccessful clinical trials on endometriosis and a few lessons learned.

  Gynecologic and obstetric investigation 20070101

• Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study.

  The Journal of rheumatology 20070101

• Patient adherence to osteoporosis medications: problems, consequences and management strategies.

  Drugs & aging 20070101

• Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).

  American journal of obstetrics and gynecology 20070101

• Raloxifene improves the ovariectomy-induced impairment in endothelium-dependent vasodilation.

  Menopause (New York, N.Y.) 20070101

• Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy.

  American journal of nephrology 20070101

• The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.

  Menopause (New York, N.Y.) 20070101

• Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.

  Journal of bone and mineral metabolism 20070101

• Bone builder vs. breast cancer.

  The Johns Hopkins medical letter health after 50 20070101

• Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia.

  BMC women's health 20070101

• Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.

  Anticancer research 20070101

• Selective estrogen receptor modulator raloxifene-associated aggravation of nonalcoholic steatohepatitis.

  Internal medicine (Tokyo, Japan) 20070101

• The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.

  Renal failure 20070101

• Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).

  Current medicinal chemistry 20070101

• Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: a framework for personalized risk assessment and counseling.

  Journal of cancer education : the official journal of the American Association for Cancer Education 20070101

• Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.

  Anticancer research 20070101

• Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene.

  International seminars in surgical oncology : ISSO 20070101

• Raloxifene similarly affects the skeletal system of male and ovariectomized female rats.

  Pharmacological reports : PR 20070101

• Effects of raloxifene on development of the methotrexate-induced changes in bone mechanical properties of male rats.

  Pharmacological reports : PR 20070101

• Interactions of the human cytosolic sulfotransferases and steroid sulfatase in the metabolism of tibolone and raloxifene.

  The Journal of steroid biochemistry and molecular biology 20070101

• Raloxifene slows down the progression of intima-media thickness in postmenopausal women.

  Menopause (New York, N.Y.) 20070101

• Vitamin D modulation of the activity of estrogenic compounds in bone cells in vitro and in vivo.

  Critical reviews in eukaryotic gene expression 20070101

• Are there any alternatives to alendronate (Fosamax) for osteoporosis to avoid the risk of osteonecrosis of the jaw?

  General dentistry 20070101

• Mechanism of collagen biosynthesis up-regulation in cultured leiomyoma cells.

  Folia histochemica et cytobiologica 20070101

• Climacteric symptom control after the addition of low-dose esterified conjugated estrogens to raloxifene standard doses.

  International journal of fertility and women's medicine 20070101

• Osteoporosis prevention and therapy: preserving and building strength through bone quality.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20061201

• Raloxifene elicits combined rapid vasorelaxation and long-term anti-inflammatory actions in rat aorta.

  The Journal of pharmacology and experimental therapeutics 20061201

• The role of P-glycoprotein in the bioactivation of raloxifene.

  Drug metabolism and disposition: the biological fate of chemicals 20061201

• Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6.

  Journal of clinical pharmacology 20061201

• Prevention of breast cancer: current state of the science and future opportunities.

  Expert opinion on investigational drugs 20061201

• Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20061201

• Effect of raloxifene on salivary sex steroid concentrations in premenopausal women.

  The Journal of endocrinology 20061201

• Non-estrogen treatments for osteoporosis: an evidence-based review.

  JAAPA : official journal of the American Academy of Physician Assistants 20061201

• Effects of raloxifene on changes in bone density.

  Collegium antropologicum 20061201

• Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration.

  Current medical research and opinion 20061201

• The cardiovascular effects of selective estrogen receptor modulators.

  Annals of the New York Academy of Sciences 20061201

• Raloxifene enhances vertebral mechanical properties independent of bone density.

  Bone 20061101

• Less calcemic Vitamin D analogs enhance creatine kinase specific activity and modulate responsiveness to gonadal steroids in the vasculature.

  The Journal of steroid biochemistry and molecular biology 20061101

• Selecting targets for cancer prevention: where do we go from here?

  Nature reviews. Cancer 20061101

• Oestradiol stimulates prolactin secretion in women through oestrogen receptors.

  Clinical endocrinology 20061101

• Raloxifene and the prevention of breast cancer.

  Expert opinion on pharmacotherapy 20061101

• Optimising endocrine approaches for the chemoprevention of breast cancer beyond the Study of Tamoxifen and Raloxifene (STAR) trial.

  European journal of cancer (Oxford, England : 1990) 20061101

• Effects of raloxifene on caveolin-1 mRNA and protein expressions in vascular smooth muscle cells.

  Acta biochimica et biophysica Sinica 20061101

• Treatment with raloxifene and 17beta-estradiol differentially modulates nitric oxide and prostanoids in venous endothelium and platelets of ovariectomized pigs.

  Journal of cardiovascular pharmacology 20061101

• Recent results from clinical trials using SERMs to reduce the risk of breast cancer.

  Annals of the New York Academy of Sciences 20061101

• Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.

  Maturitas 20061020

• Long-term raloxifene in a woman at high risk for breast cancer.

  The New England journal of medicine 20061012

• Postmenopausal advanced breast cancer: options for therapy after tamoxifen and aromatase inhibitors.

  Breast (Edinburgh, Scotland) 20061001

• Effect of raloxifene on bone mineral density in premenopausal women at increased risk of breast cancer.

  The Journal of clinical endocrinology and metabolism 20061001

• Assessment of protein oxidation in women using raloxifene.

  Molecular and cellular biochemistry 20061001

• Effectiveness of raloxifene on bone mineral density and serum lipid levels in post-menopausal women with low BMD after discontinuation of hormone replacement therapy.

  Journal of clinical pharmacy and therapeutics 20061001

• Comparative effects of estradiol, raloxifene, and genistein on the uterus of ovariectomized mice.

  Fertility and sterility 20061001

• Raloxifene works as well as tamoxifen in preventing invasive breast cancer.

  Mayo Clinic women's healthsource 20061001

• Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20061001

• Lessons from RUTH.

  Climacteric : the journal of the International Menopause Society 20061001

• The dilemma and promise of cancer chemoprevention.

  Nature clinical practice. Oncology 20061001

• Editorial: The SERM of my dreams.

  The Journal of clinical endocrinology and metabolism 20061001

• [Osteoporosis priority: Reduce the number of fractures].

  Presse medicale (Paris, France : 1983) 20061001

• [Drug treatment of postmenopausal osteoporosis. What's New in 2006].

  Presse medicale (Paris, France : 1983) 20061001

• Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib.

  Calcified tissue international 20061001

• [Effect of cyclosporine A, raloxifene and their combination on the reversion of multidrug resistance of K562/A02 line].

  Zhongguo shi yan xue ye xue za zhi 20061001

• [Menopausal hormone therapy and cardiovascular disease].

  Revista espanola de cardiologia 20061001

• Modifiers of risk of hereditary breast cancer.

  Oncogene 20060925

• Characterisation of the relaxant response to raloxifene in porcine coronary arteries.

  European journal of pharmacology 20060918

• Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep.

  American journal of physiology. Heart and circulatory physiology 20060901

• Diabetes modulates differentially creatine kinase-specific activity responsiveness to estradiol-17beta and to raloxifene in rat organs.

  Journal of cellular biochemistry 20060901

• Persistence of dysmenorrhea and nonmenstrual pain after optimal endometriosis surgery may indicate adenomyosis.

  Fertility and sterility 20060901

• On-line formation, separation, and estrogen receptor affinity screening of cytochrome P450-derived metabolites of selective estrogen receptor modulators.

  Drug metabolism and disposition: the biological fate of chemicals 20060901

• Analysis of change patterns of microcomputed tomography 3-dimensional bone parameters as a high-throughput tool to evaluate antiosteoporotic effects of agents at an early stage of ovariectomy-induced osteoporosis in mice.

  Investigative radiology 20060901

• Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis.

  Expert opinion on investigational drugs 20060901

• The science of selective estrogen receptor modulators: concept to clinical practice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060901

• Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060901

• [Molecular mechanism of tissue-specific actions of SERM].

  Clinical calcium 20060901

• [Anabolic treatment for osteoporosis: PTH treatment].

  Clinical calcium 20060901

• [Selective estrogen receptor modulators (SERMs)].

  Clinical calcium 20060901

• [SERM].

  Nihon rinsho. Japanese journal of clinical medicine 20060901

• Effects of raloxifene on platelet functions in patients with postmenopausal osteoporosis.

  Platelets 20060901

• Pulmonary benign metastasizing leiomyoma: a report of 2 cases with different outcomes.

  The Journal of reproductive medicine 20060901

• Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report.

  World journal of gastroenterology 20060828

• Raloxifene increases proliferation and up-regulates telomerase activity in human umbilical vein endothelial cells.

  The Journal of biological chemistry 20060825

• Ariad Pharmaceuticals wins first round over Eli Lilly, patents on methods can be far-reaching.

  Journal of the National Cancer Institute 20060802

• Comparative gene expression profiling reveals partially overlapping but distinct genomic actions of different antiestrogens in human breast cancer cells.

  Journal of cellular biochemistry 20060801

• Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha.

  Molecular pharmacology 20060801

• The effects of the selective estrogen receptor modulators, methyl-piperidino-pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus.

  Molecular reproduction and development 20060801

• Effect of ormeloxifene on ovariectomy-induced bone resorption, osteoclast differentiation and apoptosis and TGF beta-3 expression.

  The Journal of steroid biochemistry and molecular biology 20060801

• The changing perspective on breast cancer and chemotherapy. Three new developments are better able to predict breast cancer recurrence and chemotherapy effectiveness.

  Health news (Waltham, Mass.) 20060801

• Raloxifene can benefit prostate cancer.

  Health news (Waltham, Mass.) 20060801

• A STAR is born.

  Oncology (Williston Park, N.Y.) 20060801

• STAR trial reports.

  European journal of cancer (Oxford, England : 1990) 20060801

• Selective estrogen receptor modulators (SERMS).

  Arquivos brasileiros de endocrinologia e metabologia 20060801

• Osteoporosis treatment: raloxifene (Evista) and stroke mortality.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060718

• Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.

  The New England journal of medicine 20060713

• Risk-benefit profiles of raloxifene for women.

  The New England journal of medicine 20060713

• Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20060701

• Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer.

  Breast cancer research and treatment 20060701

• Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia.

  Metabolism: clinical and experimental 20060701

• Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.

  Current medical research and opinion 20060701

• Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20060701

• A Canadian observational study of the optimal method of transition from postmenopausal hormone therapy to raloxifene.

  Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 20060701

• Boning up on osteoporosis--current thinking on management. Interview by Emma Buchanan.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20060701

• Administration of raloxifene reduces sensorimotor and working memory deficits following traumatic brain injury.

  Behavioural brain research 20060630

• Effects of selective estrogen receptor modulator raloxifene plus 17-beta estradiol in aorta and mammary gland of female experimental atherosclerosis rabbits and possible involvement of ERK signal transduction pathway.

  The Chinese journal of physiology 20060630

• [Postmenopausal osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20060628

• Selective estrogen receptor modulators and prevention of invasive breast cancer.

  JAMA 20060621

• Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  JAMA 20060621

• Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

  JAMA 20060621

• Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.

  Cancer 20060615

• Regulation of bcl-2 expression by Ubc9.

  Experimental cell research 20060610

• Raloxifene prevails in STAR trial, may face easier road to acceptance than previous drugs.

  Journal of the National Cancer Institute 20060607

• Three-dimensional models of non-steroidal ligands: a comparative molecular field analysis.

  Steroids 20060601

• Estrogen-mediated regulation of p38 mitogen-activated protein kinase in human endometrium.

  The Journal of clinical endocrinology and metabolism 20060601

• Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene.

  Pharmacotherapy 20060601

• Long-term experience with alendronate in the treatment of osteoporosis.

  Expert opinion on pharmacotherapy 20060601

• A STARring role for raloxifene?

  The Lancet. Oncology 20060601

• Model-based drug development: the road to quantitative pharmacology.

  Journal of pharmacokinetics and pharmacodynamics 20060601

• Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20060601

• Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.

  Southern medical journal 20060601

• [The successful development of bisphosphonates in the therapy of osteoporosis].

  Medizinische Klinik (Munich, Germany : 1983) 20060601

• Raloxifene promotes adipocyte differentiation of 3T3-L1 cells.

  European journal of pharmacology 20060524

• Evaluation of ligand selectivity using reporter cell lines stably expressing estrogen receptor alpha or beta.

  Biochemical pharmacology 20060514

• Raloxifene (Evista) for breast cancer prevention in postmenopausal women.

  The Medical letter on drugs and therapeutics 20060508

• Raloxifene-induced myeloma cell apoptosis: a study of nuclear factor-kappaB inhibition and gene expression signature.

  Molecular pharmacology 20060501

• Raloxifene prevents endothelial dysfunction in aging ovariectomized female rats.

  Vascular pharmacology 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Responsiveness to estradiol-17beta and to phytoestrogens in primary human osteoblasts is modulated differentially by high glucose concentration.

  The Journal of steroid biochemistry and molecular biology 20060501

• The effect of raloxifene on cardiac autonomic regulation in osteoporotic women.

  American journal of obstetrics and gynecology 20060501

• A better option?

  Time 20060501

• [SERMs for treatment of osteoporosis: state-of-the-art and perspectives].

  Gynecologie, obstetrique & fertilite 20060501

• Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20060501

• Chemoprevention of breast cancer.

  Lancet (London, England) 20060429

• Anisotropic lattice contraction in pharmaceuticals: the influence of cryo-crystallography on calculated powder diffraction patterns.

  Journal of pharmaceutical sciences 20060401

• Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.

  BJU international 20060401

• Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.

  Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 20060401

• Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060401

• [New therapeutic approaches to osteoporosis].

  Annales d'endocrinologie 20060401

• Differential effects of chronic treatment with estrogen receptor ligands on regulation of nitric oxide synthase in porcine aortic endothelial cells.

  Journal of cardiovascular pharmacology 20060401

• [Effect of raloxifene as a SERM on bone metabolism].

  Nihon rinsho. Japanese journal of clinical medicine 20060401

• [41th Congress of EASD (European Association for The Study of Diabetes) 10 to 15 September 2005, Athens, Greece].

  La Revue de medecine interne 20060401

• Osteoporosis: how should it be treated?

  Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20060401

• Biomedical patents. Broad patent faces narrow odds in court battle.

  Science (New York, N.Y.) 20060331

• Marked sexual dimorphism of lacrimal gland peroxidase in hamster: repression by androgens and estrogens.

  Biochemical and biophysical research communications 20060324

• A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness.

  Maturitas 20060320

• Antiresorptive agents, raloxifene, and PHARMAC.

  The New Zealand medical journal 20060310

• The prevention, detection, and management of breast cancer.

  The Medical journal of Australia 20060306

• Use of raloxifene among women with a history of breast cancer.

  Breast cancer research and treatment 20060301

• The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.

  The Journal of clinical endocrinology and metabolism 20060301

• Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic sulfotransferases.

  Drug metabolism and disposition: the biological fate of chemicals 20060301

• [Molecular mechanism tissue-specific actions of selective estrogen receptor modulators].

  Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20060301

• Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.

  Medicinal chemistry (Shariqah (United Arab Emirates)) 20060301

• Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels.

  Maturitas 20060220

• The effect of raloxifene and tibolone on the uterine blood flow and endometrial thickness: a transvaginal Doppler study.

  Maturitas 20060220

• Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.

  The American journal of cardiology 20060215

• Anti-vertebral fracture efficacy of raloxifene: a meta-analysis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20060201

• [Application of anti-resorptive drugs for the treatment of osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20060201

• Raloxifene reduces fractures in postmenopausal women with osteoporosis.

  Clinical orthopaedics and related research 20060201

• [Raloxifene in postmenopausal women].

  Gynecologie, obstetrique & fertilite 20060201

• Osteoporosis: a global assessment.

  Orthopedics 20060201

• Cost-effectiveness strategies to treat osteoporosis in elderly women.

  Southern medical journal 20060201

• Effects of raloxifene on adipocytokines in Japanese osteoporotic postmenopausal women with and without type 2 diabetes.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20060201

• Quantifying the indirect treatment effect via surrogate markers.

  Statistics in medicine 20060130

• Effects of raloxifene on normal breast tissue from premenopausal women.

  Breast cancer research and treatment 20060101

• DT56a stimulates gender-specific human cultured bone cells in vitro.

  The Journal of steroid biochemistry and molecular biology 20060101

• Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20060101

• Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20060101

• The treatment of severe postmenopausal osteoporosis : a review of current and emerging therapeutic options.

  Treatments in endocrinology 20060101

• [Bisphosphonate or Raloxifene?: which drug we can choose for osteoporotic patients?].

  Clinical calcium 20060101

• Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20060101

• Does an educational leaflet improve self-reported adherence to therapy in osteoporosis? The OPTIMA study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20060101

• Influence of oestrogenic compounds on monoamine transporters in rat striatum.

  Journal of neuroendocrinology 20060101

• Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.

  Medical decision making : an international journal of the Society for Medical Decision Making 20060101

• Knowledge-based interaction fingerprint scoring: a simple method for improving the effectiveness of fast scoring functions.

  Journal of chemical information and modeling 20060101

• The future of women of minority race/ethnicity in breast cancer chemoprevention therapy.

  Ethnicity & disease 20060101

• Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy.

  Menopause (New York, N.Y.) 20060101

• Does raloxifene therapy affect mammographic breast cancer screening in postmenopausal patients?

  European journal of gynaecological oncology 20060101

• AIB1 gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines.

  BMC cancer 20060101

• Not all SERMs are created equal.

  Menopause (New York, N.Y.) 20060101

• Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.

  Menopause (New York, N.Y.) 20060101

• Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.

  Anticancer research 20060101

• Proliferative effects of different hormone regimens on mammary glands in ovariectomized rats.

  European journal of gynaecological oncology 20060101

• Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women.

  Journal of bone and mineral metabolism 20060101

• Raloxifene attenuation of 5-FU/methotrexate cytotoxicity in human breast cancer cells: the importance of sequence in combination chemotherapy.

  Anticancer research 20060101

• Raloxifene attenuation of methotrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-FU/methotrexate.

  Anticancer research 20060101

• Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.

  Menopause (New York, N.Y.) 20060101

• Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene.

  Menopause (New York, N.Y.) 20060101

• Effect of tamoxifen and raloxifene on the conjugation of bile acids with taurine and glycine in ovariectomized rats.

  Pharmacological reports : PR 20060101

• Chemoprevention of breast cancer: tamoxifen, raloxifene, and beyond.

  American journal of therapeutics 20060101

• Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.

  Menopause (New York, N.Y.) 20060101

• Effect of raloxifene on clinical fractures in Asian women with postmenopausal osteoporosis.

  Journal of bone and mineral metabolism 20060101

• [Images in intensive medicine].

  Medicina intensiva 20060101

• Estrogen and raloxifene inhibit the monocytic chemoattractant protein-1-induced migration of human monocytic cells via nongenomic estrogen receptor alpha.

  Menopause (New York, N.Y.) 20060101

• An update on breast cancer prevention trials.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• An update on raloxifene.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• Effects of 17beta-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messenger RNA in breast cancer cells.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20060101

• [Hormonal replacement therapy and selective estrogen receptor modulators in prevention of cardiovascular disease].

  Wiadomosci lekarskie (Warsaw, Poland : 1960) 20060101

• Estrogens, selective estrogen receptor modulators, and a selective estrogen receptor down-regulator inhibit endothelial production of tissue factor pathway inhibitor 1.

  BMC cardiovascular disorders 20060101

• Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).

  Breast cancer research : BCR 20060101

• Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies.

  Medical decision making : an international journal of the Society for Medical Decision Making 20060101

• Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls.

  Drugs 20060101

• Raloxifene covalently bonded to titanium implants by interfacing with (3-aminopropyl)-triethoxysilane affects osteoblast-like cell gene expression.

  International journal of immunopathology and pharmacology 20060101

• Estrogen receptor agonists and immune system in ovariectomized mice.

  International journal of immunopathology and pharmacology 20060101

• The protection against trimetrexate cytotoxicity in human bone marrow by sequence-dependent administration of raloxifene, 5-fluorouracil/trimetrexate.

  Anticancer research 20060101

• Raloxifene does not affect the changes in bone histomorphometric parameters induced by low dose tacrolimus in male rats.

  Acta poloniae pharmaceutica 20060101

• [Current status of breast cancer chemoprevention].

  Revista da Associacao Medica Brasileira (1992) 20060101

• Is raloxifene ready to be used for prevention of breast cancer?

  International journal of fertility and women's medicine 20060101

• [Osteoporosis treatment in Portugal: trends and geographical variation].

  Acta medica portuguesa 20060101

• ERE-independent ERalpha target genes differentially expressed in human breast tumors.

  Molecular and cellular endocrinology 20051221

• Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis?

  European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20051201

• Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.

  Steroids 20051201

• Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifene.

  Contemporary clinical trials 20051201

• A new selective estrogen receptor modulator, CHF 4227.01, preserves bone mass and microarchitecture in ovariectomized rats.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20051201

• Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?

  Best practice & research. Clinical rheumatology 20051201

• Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study.

  Arthritis and rheumatism 20051201

• Effect of raloxifene on aortic elasticity in healthy postmenopausal women.

  American heart journal 20051201

• Procoagulant state after raloxifene therapy in postmenopausal women.

  Fertility and sterility 20051201

• Therapeutic dosages of raloxifene do not modify myeloperoxidase and F2alpha-isoprostane levels in postmenopausal women.

  Fertility and sterility 20051201

• The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.

  Current medical research and opinion 20051201

• High risk of osteopenia and bone derangement in postsurgical patients with craniopharyngiomas, pituitary adenomas and other parasellar lesions.

  Endocrine journal 20051201

• A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.

  Journal of medicinal chemistry 20051103

• Estrogenic regulation of tissue factor and tissue factor pathway inhibitor in platelets.

  American journal of physiology. Heart and circulatory physiology 20051101

• Expression profiling of rat femur revealed suppression of bone formation genes by treatment with alendronate and estrogen but not raloxifene.

  Molecular pharmacology 20051101

• Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice.

  The Journal of steroid biochemistry and molecular biology 20051101

• [Implications of estrogens and their receptors for the development and progression of prostate cancer].

  Der Pathologe 20051101

• Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20051101

• A rational approach to evidence gaps in the management of osteoporosis.

  The American journal of medicine 20051101

• What can be done about bone loss and what are the current treatments for it?

  Health news (Waltham, Mass.) 20051101

• The role of non-calcemic analogs of vitamin D in differentiation of cultured rat bone marrow into osteoblast-like cells: age and sex differences.

  Journal of endocrinological investigation 20051101

• Comparing raloxifene with continuous combined estrogen-progestin therapy in postmenopausal women: Review of Euralox 1.

  Maturitas 20051016

• Modulator recognition factor 1, an AT-rich interaction domain family member, is a novel corepressor for estrogen receptor alpha.

  Molecular endocrinology (Baltimore, Md.) 20051001

• HPLC analysis of raloxifene hydrochloride and its application to drug quality control studies.

  Pharmacological research 20051001

• The effects of short-term raloxifene therapy on fibrinolysis markers: TAFI, tPA, and PAI-1.

  Acta obstetricia et gynecologica Scandinavica 20051001

• The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: a randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women.

  American journal of obstetrics and gynecology 20051001

• Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.

  Journal of the Society for Gynecologic Investigation 20051001

• Activity of estradiol and selective estrogen receptor modulators in the mouse N20.1 oligodendrocyte/astrocytes cell line.

  Neuro endocrinology letters 20051001

• Review of treatment modalities for postmenopausal osteoporosis.

  Southern medical journal 20051001

• [Modification of C3 and C4 levels after the administration of conjugated estrogens plus medroxiprogesterone or raloxifene in postmenopausal women].

  Ginecologia y obstetricia de Mexico 20051001

• A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.

  Maturitas 20050916

• Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity.

  Endocrinology 20050901

• Effects of oestrogen receptor-active compounds on lipid metabolism.

  Diabetes, obesity & metabolism 20050901

• Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20050901

• Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study.

  Chemical research in toxicology 20050901

• Safety assessment of raloxifene over eight years in a clinical trial setting.

  Current medical research and opinion 20050901

• [Effects of raloxifene on bone biomarkers in postmenopausal women on maintenance haemodialysis].

  Clinical calcium 20050901

• Apoptosis and proliferation in breast cancer cells, cultured in vitro: effects of SERMs.

  Climacteric : the journal of the International Menopause Society 20050901

• The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation.

  Journal of immunology (Baltimore, Md. : 1950) 20050815

• Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20050801

• BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20050801

• Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats.

  Endocrinology 20050801

• Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.

  Drug metabolism and disposition: the biological fate of chemicals 20050801

• Vitamin D insufficiency does not affect bone mineral density response to raloxifene.

  The Journal of clinical endocrinology and metabolism 20050801

• Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women.

  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 20050801

• Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.

  International journal of oncology 20050801

• Effect of estradiol and raloxifene on MUC1 expression and adhesive properties of Ishikawa cells.

  Oncology reports 20050801

• Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.

  Calcified tissue international 20050801

• Differing patterns of antiresorptive pharmacotherapy in nursing facility residents and community dwellers.

  Journal of the American Geriatrics Society 20050801

• Raloxifene increases serum leptin levels in postmenopausal women: a prospective study.

  American journal of obstetrics and gynecology 20050801

• Estrogen and extracellular matrix influence human gingival fibroblast proliferation and protein production.

  Journal of periodontology 20050801

• Altered level of apurinic/apyrimidinic endonuclease/redox factor-1 (APE/REF-1) mRNA in the hippocampus of ovariectomized rats treated by raloxifene against kainic acid.

  Clinical and experimental pharmacology & physiology 20050801

• A short-incubation reporter-gene assay for high-throughput screening of estrogen receptor-alpha antagonists.

  Assay and drug development technologies 20050801

• [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].

  Ginecologia y obstetricia de Mexico 20050801

• Discovery of high-affinity ligands of sigma1 receptor, ERG2, and emopamil binding protein by pharmacophore modeling and virtual screening.

  Journal of medicinal chemistry 20050728

• Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3.

  Maturitas 20050716

• Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release.

  Molecular and cellular endocrinology 20050715

• Differential effects of 17beta-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins.

  American journal of physiology. Endocrinology and metabolism 20050701

• Raloxifene relaxes rat intrarenal arteries by inhibiting Ca2+ influx.

  American journal of physiology. Renal physiology 20050701

• Anticancer multidrug resistance mediated by MRP1: recent advances in the discovery of reversal agents.

  Medicinal research reviews 20050701

• Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women.

  The Journal of clinical endocrinology and metabolism 20050701

• Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy.

  Diabetes care 20050701

• Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.

  Metabolism: clinical and experimental 20050701

• Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women.

  Fertility and sterility 20050701

• [Effect of raloxifene and estradiol on the biological function and osteoprotegerin expression of osteoblasts in vitro].

  Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA 20050701

• Raloxifene for prevention of osteoporotic fractures.

  American family physician 20050701

• Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20050701

• Endometrial lesions causing uterine bleeding in postmenopausal women receiving raloxifene.

  Maturitas 20050616

• Mouse estrogen receptor beta isoforms exhibit differences in ligand selectivity and coactivator recruitment.

  Biochemistry 20050607

• Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor.

  Carcinogenesis 20050601

• Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10.

  Drug metabolism and disposition: the biological fate of chemicals 20050601

• Estrogen and raloxifene, a selective estrogen receptor modulator, ameliorate renal damage in db/db mice.

  The American journal of pathology 20050601

• A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

  Health technology assessment (Winchester, England) 20050601

• [Raloxifene and bone quality issues].

  Clinical calcium 20050601

• Raloxifene promotes prostacyclin release in human endothelial cells through a mechanism that involves cyclooxygenase-1 and -2.

  Fertility and sterility 20050601

• Breast cancer chemoprevention: a review of selective estrogen receptor modulators.

  Clinical journal of oncology nursing 20050601

• Effect of tamoxifen and raloxifene on cholesterol transformation to bile acids in ovariectomized rats.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20050601

• Raloxifene for hormone replacement therapy (HRT).

  The New Zealand medical journal 20050506

• Safety profile of raloxifene as used in general practice in England: results of a prescription-event monitoring study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20050501

• Differential effects of 17beta-estradiol, conjugated equine estrogen, and raloxifene on mRNA expression, aggregation, and secretion in platelets.

  American journal of physiology. Heart and circulatory physiology 20050501

• Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands.

  The Journal of endocrinology 20050501

• Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.

  Obstetrics and gynecology 20050501

• Magnetic resonance spectroscopic comparison of the effects of resveratrol (3,4',5-trihydroxy stilbene) to conjugated equine estrogen, tibolone and raloxifene on ovariectomized rat brains.

  European journal of obstetrics, gynecology, and reproductive biology 20050501

• New help for old bones.

  Nursing 20050501

• Estrogen increases collagen I and III mRNA expression in the pelvic support tissues of the rhesus macaque.

  American journal of obstetrics and gynecology 20050501

• Effectiveness and safety of raloxifene in post-menopausal females.

  Journal of the College of Physicians and Surgeons--Pakistan : JCPSP 20050501

• Raloxifene and colorectal cancer.

  Journal of women's health (2002) 20050501

• Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20050501

• Differential effects of alternatives to hormone replacement therapy in postmenopausal healthy women.

  Danish medical bulletin 20050501

• Efficient access to 2-aryl-3-substituted benzo[b]thiophenes.

  The Journal of organic chemistry 20050429

• Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.

  Maturitas 20050411

• Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.

  Maturitas 20050411

• [Raloxifene for the treatment of osteoporosis].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20050410

• Re: Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

  Journal of the National Cancer Institute 20050406

• 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds.

  Circulation 20050405

• Chronic estrogenic drug treatment increases preproenkephalin mRNA levels in the rat striatum and nucleus accumbens.

  Psychoneuroendocrinology 20050401

• Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus.

  Biology of reproduction 20050401

• Searching for methods to detect, prevent, and treat Alzheimer's disease.

  The American journal of psychiatry 20050401

• Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.

  The American journal of psychiatry 20050401

• Raloxifene pharmacokinetics in males with normal and impaired renal function.

  British journal of clinical pharmacology 20050401

• [Effects of estrogen and selective estrogen receptor modulators on osteoporosis].

  Clinical calcium 20050401

• [SERMs: an update for clinicians].

  Clinical calcium 20050401

• Effect of tamoxifen, raloxifen and tibolon on bile components in ovariectomized rats.

  European journal of obstetrics, gynecology, and reproductive biology 20050401

• Treatment of adolescents with gynecomastia.

  The Journal of pediatrics 20050401

• Transcriptional activation of the oxytocin promoter by oestrogens uses a novel non-classical mechanism of oestrogen receptor action.

  Journal of neuroendocrinology 20050401

• Molecular mechanism of action of selective estrogen receptor modulator in target tissues.

  Endocrine journal 20050401

• Anti-growth factor activities of benzothiophenes in human breast cancer cells.

  The Journal of steroid biochemistry and molecular biology 20050401

• Hormone replacement therapy--differing guidelines.

  South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 20050401

• Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen.

  Cancer letters 20050318

• Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene.

  Biochemical pharmacology 20050315

• Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women.

  Maturitas 20050314

• Selective estrogen-receptor modulators for primary prevention of breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050310

• Raloxifene relaxes rat pulmonary arteries and veins: roles of gender, endothelium, and antagonism of Ca2+ influx.

  The Journal of pharmacology and experimental therapeutics 20050301

• The putative tumor suppressor deleted in malignant brain tumors 1 is an estrogen-regulated gene in rodent and primate endometrial epithelium.

  Endocrinology 20050301

• Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures.

  The Journal of clinical endocrinology and metabolism 20050301

• Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.

  Bioorganic & medicinal chemistry letters 20050301

• Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior.

  NeuroImage 20050301

• Oral antiresorptive therapy.

  Current rheumatology reports 20050301

• Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen.

  Menopause (New York, N.Y.) 20050301

• Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women.

  Menopause (New York, N.Y.) 20050301

• Changes in 5-HT1A receptor binding and G-protein activation in the rat brain after estrogen treatment: comparison with tamoxifen and raloxifene.

  Journal of psychiatry & neuroscience : JPN 20050301

• Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.

  Climacteric : the journal of the International Menopause Society 20050301

• [Selective estrogen receptor modulator (SERM)].

  Nihon rinsho. Japanese journal of clinical medicine 20050301

• [Treatment of osteoporosis with antiresorptive drugs].

  Ugeskrift for laeger 20050221

• [Osteoporosis in the elderly--diagnosis and treatment].

  MMW Fortschritte der Medizin 20050217

• Antidepressant augmentation with raloxifene.

  Journal of clinical psychopharmacology 20050201

• Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study.

  Liver international : official journal of the International Association for the Study of the Liver 20050201

• Methyl mercury influences growth-related signaling in MCF-7 breast cancer cells.

  Environmental toxicology 20050201

• Progressive pigmentary purpura related to raloxifene.

  Saudi medical journal 20050201

• Beneficial effects of raloxifene and atorvastatin on serum lipids.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20050201

• Estradiol and raloxifene protect cultured SN4741 neurons against oxidative stress.

  Neuroscience letters 20050120

• Ab initio quantum mechanical study of the binding energies of human estrogen receptor alpha with its ligands: an application of fragment molecular orbital method.

  Journal of computational chemistry 20050115

• Repercussions of raloxifen, tamoxifen and estrogen on aortic atherosclerotic lesions of female rabbits submitted to ovariectomy and hypercholesterol diet.

  Maturitas 20050110

• Prevention of hormone-related cancers: breast cancer.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050110

• Gene expression changes induced by estrogen and selective estrogen receptor modulators in primary-cultured human endometrial cells: signals that distinguish the human carcinogen tamoxifen.

  Toxicology 20050105

• Protection of bone mass by estrogens and raloxifene during exercise-induced weight Loss.

  The Journal of clinical endocrinology and metabolism 20050101

• Examination of 209 drugs for inhibition of cytochrome P450 2C8.

  Journal of clinical pharmacology 20050101

• Raloxifene does not prevent fibrinogen oxidation in vitro.

  Medical science monitor : international medical journal of experimental and clinical research 20050101

• Gonadotrope oestrogen receptor-alpha and -beta and progesterone receptor immunoreactivity after ovariectomy and exposure to oestradiol benzoate, tamoxifen or raloxifene in the rat: correlation with LH secretion.

  The Journal of endocrinology 20050101

• TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20050101

• Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20050101

• CORE breast-cancer prevention trial.

  The Lancet. Oncology 20050101

• [Raloxifene hydrochloride (Evista Tablet 60 mg) for postmenopausal osteoporosis: mode of action and clinical efficacy].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20050101

• Restoration of endothelial function via enhanced nitric oxide synthesis after long-term treatment of raloxifene in adult hypertensive rats.

  Arzneimittel-Forschung 20050101

• Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis.

  Renal failure 20050101

• Interleukin-18 (IL-18) and matrix metalloproteinase-9 (MMP-9) in post-menopausal osteoporosis.

  Archives of gerontology and geriatrics 20050101

• Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.

  Thrombosis research 20050101

• Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.

  Current medical research and opinion 20050101

• Pharmacological management of severe postmenopausal osteoporosis.

  Drugs & aging 20050101

• Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene.

  Journal of bone and mineral metabolism 20050101

• Raloxifene and teriparatide (hPTH 1-34) have complementary effects on the osteopenic skeleton of ovariectomized rats.

  Journal of bone and mineral metabolism 20050101

• Differential effects of genistein, estradiol and raloxifene on rat osteoclasts in vitro.

  Pharmacological reports : PR 20050101

• Effects of resveratrol, raloxifene, tibolone and conjugated equine estrogen on vaginal squamous cell maturation of ovariectomized rats.

  Gynecologic and obstetric investigation 20050101

• Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene.

  Menopause (New York, N.Y.) 20050101

• Benefit-risk assessment of raloxifene in postmenopausal osteoporosis.

  Drug safety 20050101

• Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20050101

• Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds.

  Journal of investigative surgery : the official journal of the Academy of Surgical Research 20050101

• Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy.

  Menopause (New York, N.Y.) 20050101

• Hormonal environment in the induction of breast cancer in castrated rats using dimethylbenzanthracene: influence of the presence or absence of ovarian activity and of treatment with estradiol, tibolone, and raloxifene.

  Menopause (New York, N.Y.) 20050101

• Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women.

  Journal of endocrinological investigation 20050101

• Women's decision making about whether or not to use breast cancer chemoprevention.

  Women & health 20050101

• Counterfeit drug warning.

  FDA consumer 20050101

• Raloxifene reduces urokinase-type plasminogen activator-dependent proliferation of synoviocytes from patients with rheumatoid arthritis.

  Arthritis research & therapy 20050101

• Decision rule based multiplicity adjustment strategy.

  Clinical trials (London, England) 20050101

• Anabolic therapy for osteoporosis.

  International journal of fertility and women's medicine 20050101

• Aggressive angiomyxoma of the perineum.

  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 20050101

• Raloxifene and cardiovascular health: its relationship to lipid and glucose metabolism, hemostatic and inflammation factors and cardiovascular function in postmenopausal women.

  Current pharmaceutical design 20050101

• Identifying methodologies in the assessment of treatment effects on the repeated occurrences of hot flashes in postmenopausal women.

  Clinical trials (London, England) 20050101

• Expression of steroid receptors in intact rat uterus, mammary gland, and liver treated with selective estrogen receptor modulators and conjugated equine estrogens.

  Advances in therapy 20050101

• Raloxifene: bone and cardiovascular effects.

  Journal of endocrinological investigation 20050101

• [Raloxifene (Evista) in the treatment of postmenopausal osteoporosis--the profile of the patient].

  Reumatizam 20050101

• Chemoprevention of breast cancer in postmenopausal women.

  Breast disease 20050101

• Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs).

  Breast disease 20050101

• Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women.

  The American journal of cardiology 20041201

• Defining the role of raloxifene for the prevention of breast cancer.

  Journal of the National Cancer Institute 20041201

• Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

  Journal of the National Cancer Institute 20041201

• [Evaluation of osteoporosis treatment efficacy by bone mass measurement].

  Clinical calcium 20041201

• Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study.

  The Journal of clinical endocrinology and metabolism 20041201

• HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal women.

  Fertility and sterility 20041201

• Both estrogen and raloxifene protect against beta-amyloid-induced neurotoxicity in estrogen receptor alpha-transfected PC12 cells by activation of telomerase activity via Akt cascade.

  The Journal of endocrinology 20041201

• Predictors of hot flushes in postmenopausal women who receive raloxifene therapy.

  American journal of obstetrics and gynecology 20041201

• Oral antiresorptive therapy.

  Current osteoporosis reports 20041201

• Selective estrogen receptor modulators prevent neointima formation after vascular injury.

  Molecular and cellular endocrinology 20041130

• Effects of ovarian steroids and raloxifene on proteins that synthesize, transport, and degrade serotonin in the raphe region of macaques.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20041101

• Selective oestrogen receptor modulators in desmoid tumours.

  Expert opinion on investigational drugs 20041101

• [Menopause in 2004: 'hormone replacement therapy' is not what it used to be anymore].

  La Revue de medecine interne 20041101

• Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.

  The American journal of cardiology 20041101

• Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography.

  Bone 20041101

• Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures.

  Journal of endocrinological investigation 20041101

• [Selective estrogen receptor modulators].

  Polskie Archiwum Medycyny Wewnetrznej 20041101

• Endogenous estrogen levels affect sexual function in elderly post-menopausal women.

  Maturitas 20041015

• Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.

  Obstetrics and gynecology 20041001

• Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.

  The Journal of family practice 20041001

• Endocrine therapy for early breast cancer.

  Expert review of anticancer therapy 20041001

• In vivo properties of the urinary bladder wall and their modulation by estradiol and raloxifene in a rat model.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20041001

• Pharmacologic prevention of osteoporotic fractures.

  American family physician 20041001

• Effect of hormone replacement therapy on the elemental contents of uterine tissue.

  Biological trace element research 20041001

• Treating osteoporosis in post-menopausal women: a case approach.

  Cleveland Clinic journal of medicine 20041001

• [Hormone therapy for uterine corpus cancer--introduction].

  Nihon rinsho. Japanese journal of clinical medicine 20041001

• [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].

  Clinical calcium 20041001

• [Contribution of bone quality to fracture risk].

  Clinical calcium 20041001

• [Relationship between changes in biochemical markers of bone turnover and prediction value of fracture risk].

  Clinical calcium 20041001

• [Additional effect of SERM: mammary gland].

  Clinical calcium 20041001

• [Effects of raloxifene on other organs without bone: uterus].

  Clinical calcium 20041001

• [Cardiovascular effects of SERM].

  Clinical calcium 20041001

• [Additional effect of SERM: central nervous system].

  Clinical calcium 20041001

• [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].

  Clinical calcium 20041001

• [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].

  Clinical calcium 20041001

• [SERM and quality of bone].

  Clinical calcium 20041001

• [Safety profile of raloxifene].

  Clinical calcium 20041001

• [Which is the better choice, estrogen or SERMs in postmenopausal women?].

  Clinical calcium 20041001

• [Who are the candidates for the treatment by raloxifen ?].

  Clinical calcium 20041001

• Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20041001

• [Menopausal hormonal therapies: impact on mammographic breast density].

  Journal de radiologie 20041001

• Latest innovation in the treatment of osteoporosis: SERMs and the role of parathyroid hormone.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20041001

• Differential effects of raloxifene and tamoxifen on the expression of estrogen receptors and antigen Ki-67 in human endometrial adenocarcinoma cell line.

  Oncology reports 20040901

• Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040901

• Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.

  Journal of the American Geriatrics Society 20040901

• Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women.

  The Journal of endocrinology 20040901

• Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women.

  Fertility and sterility 20040901

• Spectrophotometric analysis of raloxifene hydrochloride in pure and pharmaceutical formulations.

  Die Pharmazie 20040901

• Management of osteoporosis in Hong Kong.

  Clinical calcium 20040901

• Diabetes, impaired fasting glucose, and development of cognitive impairment in older women.

  Neurology 20040824

• Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040815

• Structural basis for the deactivation of the estrogen-related receptor gamma by diethylstilbestrol or 4-hydroxytamoxifen and determinants of selectivity.

  The Journal of biological chemistry 20040806

• Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040801

• Raloxifene and its role in breast cancer prevention.

  Expert review of anticancer therapy 20040801

• Effects of clomiphene and raloxifene on gonadotrophin secretion in postmenopausal women: evidence of nongenomic action.

  Clinical endocrinology 20040801

• Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial.

  The Journal of clinical endocrinology and metabolism 20040801

• Effect of hormone therapy, tibolone and raloxifene on circulating vascular endothelial growth factor in Greek postmenopausal women.

  European journal of endocrinology 20040801

• Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study.

  Fertility and sterility 20040801

• Gonadotropin-releasing hormone agonist with or without raloxifene: effects on cognition, mood, and quality of life.

  Fertility and sterility 20040801

• Estrogenic activity of glabridin and glabrene from licorice roots on human osteoblasts and prepubertal rat skeletal tissues.

  The Journal of steroid biochemistry and molecular biology 20040801

• National trends in osteoporosis visits and osteoporosis treatment, 1988-2003.

  Archives of internal medicine 20040726

• Compliance with drug therapies for the treatment and prevention of osteoporosis.

  Maturitas 20040715

• Raloxifene lowers ischaemia susceptibility by increasing nitric oxide generation in the heart of ovariectomized rats in vivo.

  European journal of pharmacology 20040714

• Lead identification of a potent benzopyranone selective estrogen receptor modulator.

  Bioorganic & medicinal chemistry letters 20040705

• Disposition mechanisms of raloxifene in the human intestinal Caco-2 model.

  The Journal of pharmacology and experimental therapeutics 20040701

• Estrogen and raloxifene modulate leptin and its receptor in hypothalamus and adipose tissue from ovariectomized rats.

  Endocrinology 20040701

• Effects of raloxifene and estradiol on hippocampal acetylcholine release and spatial learning in the rat.

  Psychoneuroendocrinology 20040701

• Raloxifene relaxes rat cerebral arteries in vitro and inhibits L-type voltage-sensitive Ca2+ channels.

  Stroke 20040701

• A new selective estrogen receptor modulator HMR-3339 fully corrects bone alterations induced by ovariectomy in adult rats.

  Bone 20040701

• Effect of raloxifene on urinary incontinence: a randomized controlled trial.

  Obstetrics and gynecology 20040701

• Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia.

  The Journal of pediatrics 20040701

• Hormonal manipulation of benign metastasizing leiomyomas: report of two cases and review of the literature.

  The Journal of clinical endocrinology and metabolism 20040701

• Oxidation of raloxifene to quinoids: potential toxic pathways via a diquinone methide and o-quinones.

  Chemical research in toxicology 20040701

• Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women.

  Current medical research and opinion 20040701

• Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.

  Chinese medical journal 20040701

• Estrogen-like activity of licorice root constituents: glabridin and glabrene, in vascular tissues in vitro and in vivo.

  The Journal of steroid biochemistry and molecular biology 20040701

• Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.

  American journal of obstetrics and gynecology 20040701

• Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.

  Human reproduction (Oxford, England) 20040601

• Differential effects of estradiol, raloxifene and tamoxifen on estrogen receptor expression in cultured human skin fibroblasts.

  International journal of molecular medicine 20040601

• Raloxifene improves coronary perfusion, cardiac contractility, and myocardial metabolism in the ischemic heart: role of phosphatidylinositol 3-kinase/Akt pathway.

  Journal of cardiovascular pharmacology 20040601

• Does raloxifene inhibit the growth of uterine fibroids?

  Fertility and sterility 20040601

• Effects of raloxifene hydrochloride on endometrial cancer cells in vitro.

  Gynecologic oncology 20040601

• Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20040601

• Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action.

  Clinical therapeutics 20040601

• Comparison of raloxifene and atorvastatin effects on serum lipids composition of healthy post-menopausal women.

  Molecular and cellular biochemistry 20040601

• Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20040601

• A reappraisal of therapeutic approaches to osteoporosis.

  Aging clinical and experimental research 20040601

• Effects of raloxifene on mood, sleep, libido and cognitive function in postmenopausal healthy women: a pilot study.

  Maturitas 20040528

• Prevention of osteoporosis and osteoporotic fractures in postmenopausal women: recommendation statement from the Canadian Task Force on Preventive Health Care.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20040525

• [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].

  MMW Fortschritte der Medizin 20040520

• Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current.

  British journal of pharmacology 20040501

• Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040501

• Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040501

• The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.

  Journal of the American Geriatrics Society 20040501

• Value of SERMs in postmenopausal women.

  Lancet (London, England) 20040501

• Uterine effects of estrogen plus progestin therapy and raloxifene: adjudicated results from the EURALOX study.

  Obstetrics and gynecology 20040501

• Cardiovascular effects of raloxifene: the arterial and venous systems.

  American heart journal 20040501

• Effects of the selective estrogen receptor modulator LY117018 on growth hormone secretion: In vitro studies.

  Metabolism: clinical and experimental 20040501

• Refining clinical practice: transforming science research into the art of medicine.

  Annals of the Academy of Medicine, Singapore 20040501

• Inhibition of low-density lipoprotein and high-density lipoprotein oxidation by raloxifene.

  Journal of women's health (2002) 20040501

• Effect of raloxifene and its interaction with human PTH on bone formation.

  Journal of endocrinological investigation 20040501

• Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20040501

• [Bone quality in treatment with raroxifene ].

  Clinical calcium 20040501

• A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

  Archives of internal medicine 20040426

• Cloning and functional characterization of PELP1/MNAR promoter.

  Gene 20040414

• Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.

  Journal of internal medicine 20040401

• Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.

  Journal of molecular endocrinology 20040401

• Raloxifene decreases serum IGF-I in male patients with active acromegaly.

  European journal of endocrinology 20040401

• Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men.

  European journal of endocrinology 20040401

• Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20040401

• [Bone quality and raloxifene].

  Clinical calcium 20040401

• Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study.

  Maturitas 20040315

• Development and validation of a quantitative assay for raloxifene by capillary electrophoresis.

  Journal of pharmaceutical and biomedical analysis 20040310

• [Effects of different treatments for osteoporosis on prevention of fractures: toward and individualized and economic approach].

  Praxis 20040310

• New ways with old bones. Osteoporosis researchers look for drugs to replace hormone replacement therapy.

  Lancet (London, England) 20040306

• Hormone alternative doesn't worsen vasomotor symptoms or impact urinary incontinence in post-menopausal women.

  Report on medical guidelines & outcomes research 20040305

• [Delaying degeneration or promoting regeneration. 2 successful strategies in osteoporosis].

  MMW Fortschritte der Medizin 20040304

• Endocrine prevention of breast cancer using selective oestrogen receptor modulators (SORMs).

  Best practice & research. Clinical endocrinology & metabolism 20040301

• Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.

  Molecular biology of the cell 20040301

• Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women.

  Diabetologia 20040301

• Osteoporosis: underrated, underdiagnosed and undertreated.

  The Medical journal of Australia 20040301

• The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial.

  The Journal of clinical endocrinology and metabolism 20040301

• Insights into the molecular biology of the estrogen receptor define novel therapeutic targets for breast cancer.

  European journal of endocrinology 20040301

• Mechanisms for altered reproductive function in female rats following neonatal administration of raloxifene.

  European journal of endocrinology 20040301

• Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20040301

• Selective estrogen receptor modulation: concept and consequences in cancer.

  Cancer cell 20040301

• Osteoporosis--diagnosis, treatment and management.

  Australian family physician 20040301

• [Evidence-based medicine and drug selection of osleoporosis prevention after menopause].

  Zhonghua yi xue za zhi 20040217

• [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].

  Zhonghua yi xue za zhi 20040217

• Interplay between estrogen response element sequence and ligands controls in vivo binding of estrogen receptor to regulated genes.

  The Journal of biological chemistry 20040206

• 17beta-estradiol downregulates beta3-integrin expression in differentiating and mature human osteoclasts.

  Journal of cellular physiology 20040201

• Raloxifene prevents cardiac hypertrophy and dysfunction in pressure-overloaded mice.

  Hypertension (Dallas, Tex. : 1979) 20040201

• Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene.

  Human reproduction (Oxford, England) 20040201

• Effect of raloxifene on urinary incontinence: a randomized controlled trial.

  Obstetrics and gynecology 20040201

• Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.

  Obstetrics and gynecology 20040201

• Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.

  Bone 20040201

• Raloxifene therapy in postmenopausal women is associated with a significant reduction in the concentration of serum vascular endothelial growth factor.

  Fertility and sterility 20040201

• Progress in chemoprevention of breast cancer.

  Critical reviews in oncology/hematology 20040201

• [MORE study(raloxifene)].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• [Raloxifene hydrochloride].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• [Prevention of fractures with therapeutic agents for osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• [Quality of life before and after medical treatments in osteoporosis patients].

  Nihon rinsho. Japanese journal of clinical medicine 20040201

• Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study.

  Clinical therapeutics 20040201

• Therapeutic targeting in the estrogen receptor hormonal pathway.

  Seminars in oncology 20040201

• Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus.

  The Journal of steroid biochemistry and molecular biology 20040201

• Treatment with non-hypercalcemic analogs of 1,25-dihydroxyvitamin D3 increases responsiveness to 17beta-estradiol, dihydrotestosterone or raloxifene in primary human osteoblasts.

  The Journal of steroid biochemistry and molecular biology 20040201

• Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.

  Oncogene 20040115

• [Postmenopausal osteoporosis].

  Orvosi hetilap 20040104

• Raloxifene inhibits cholesterol aortic content but not atherosclerotic plaque size in oophorectomised cholesterol-fed rabbits.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20040101

• Comparative analysis of oestrogen and raloxifene effects on the phospholipid composition of high density lipoproteins in healthy postmenopausal women.

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20040101

• Recurrent vulval fibroids--an unusual indication for selective oestrogen receptor modulators (SERMs).

  Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology 20040101

• Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease.

  Experimental neurology 20040101

• Potent inhibition of human liver aldehyde oxidase by raloxifene.

  Drug metabolism and disposition: the biological fate of chemicals 20040101

• Raloxifene prevents the growth of uterine leiomyomas in premenopausal women.

  Fertility and sterility 20040101

• Raloxifene reduces procarboxypeptidase U, an antifibrinolytic marker. A 2-year randomized, placebo-controlled study in healthy early postmenopausal women.

  Menopause (New York, N.Y.) 20040101

• [Raloxifene and breast: from the SERMs concept to its place in clinical practice].

  Gynecologie, obstetrique & fertilite 20040101

• Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.

  Menopause (New York, N.Y.) 20040101

• A one-year follow-up on the effects of raloxifene on thyroid function in postmenopausal women.

  Menopause (New York, N.Y.) 20040101

• High glucose blocks the effects of estradiol on human vascular cell growth: differential interaction with estradiol and raloxifene.

  The Journal of steroid biochemistry and molecular biology 20040101

• [Chemoprevention of breast cancer. Clinical trials in pharmacological prevention].

  Medicina 20040101

• The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.

  The oncologist 20040101

• Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women.

  Endocrine 20040101

• Effect of raloxifene on quality of life: a prospective study using the Utian Quality of Life (UQOL) Scale.

  Menopause (New York, N.Y.) 20040101

• The effect of hormone therapy and raloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women.

  Menopause (New York, N.Y.) 20040101

• Estrogen receptor profiles: changes in mouse and rat mammary tumors by treatment with selective estrogen receptor modifiers.

  Medical principles and practice : international journal of the Kuwait University, Health Science Centre 20040101

• Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis.

  Menopause (New York, N.Y.) 20040101

• Raloxifene increases the capacity of serum to promote prostacyclin release in human endothelial cells: implication of COX-1 and COX-2.

  Menopause (New York, N.Y.) 20040101

• Prevention of osteoporosis and uterine effects in post-menopausal women taking raloxifene for 5 years.

  Menopause (New York, N.Y.) 20040101

• The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial.

  Connecticut medicine 20040101

• Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.

  European review for medical and pharmacological sciences 20040101

• Mood modifications with raloxifene and continuous combined estrogen plus progestin hormone therapy.

  International journal of fertility and women's medicine 20040101

• Chemoprevention of breast cancer.

  Current problems in cancer 20040101

• Hormone therapy and selective estrogen receptor modulators for prevention of coronary heart disease in postmenopausal women estrogen replacement from the cardiologist's perspective.

  Cardiology in review 20040101

• [Compression vertebral fracture in osteoporosis--prevention and treatment].

  Reumatizam 20040101

• Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

  International journal of clinical pharmacology research 20040101

• [Selective estrogen receptor modulator].

  Clinical calcium 20040101

• Raloxifene rebound regression.

  Cancer investigation 20040101

• Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.

  PharmacoEconomics 20040101

• [Update 2004. Osteoporosis--management--current status].

  Krankenpflege Journal 20040101

• Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications.

  Treatments in endocrinology 20040101

• Identification of transcriptional biomarkers induced by SERMS in human endometrial cells using multivariate analysis of DNA microarrays.

  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20040101

• [New prevention strategies against breast cancer and cervical carcinoma. What can you advice to your patients].

  MMW Fortschritte der Medizin 20031211

• [Therapy of postmenopausal osteoporosis].

  Der Orthopade 20031201

• Pharmacological prevention of breast cancer: quo vadis?

  Breast (Edinburgh, Scotland) 20031201

• Compliance of osteoporotic patients with different treatment regimens.

  The Israel Medical Association journal : IMAJ 20031201

• Effect of raloxifene on insulin-like growth factor-I, insulin-like growth factor binding protein-3, and leptin in premenopausal women at high risk for developing breast cancer.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20031201

• Characterization of a membrane-associated estrogen receptor in a rat hypothalamic cell line (D12).

  Endocrine 20031201

• Glycosaminoglycan profile in bladder and urethra of castrated rats treated with estrogen, progestogen, and raloxifene.

  American journal of obstetrics and gynecology 20031201

• An approach to postmenopausal osteoporosis treatment: a case study review.

  Journal of the American Academy of Nurse Practitioners 20031201

• Transition to raloxifene with and without low-dose estrogen therapy in postmenopausal women: effects on serum lipids and fibrinogen - a pilot study.

  Climacteric : the journal of the International Menopause Society 20031201

• Osteoporosis management in the new millennium.

  Primary care 20031201

• Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis.

  Endocrine regulations 20031201

• Hormone therapy after endometrial cancer.

  The journal of the British Menopause Society 20031201

• Skeletal and nonskeletal effects of raloxifene.

  Current osteoporosis reports 20031201

• Playing the old piano: another tune for endocrine therapy?

  Journal of the National Cancer Institute 20031105

• Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo.

  Journal of the National Cancer Institute 20031105

• Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts.

  International journal of molecular medicine 20031101

• 2-methoxyestradiol strongly inhibits human uterine sarcomatous cell growth.

  Gynecologic oncology 20031101

• The role of selective estrogen receptor modulators (SERMs) in postmenopausal health.

  Annals of the New York Academy of Sciences 20031101

• Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line.

  The Journal of biological chemistry 20031031

• Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20031001

• Osteoporosis: evaluation and treatment.

  Current women's health reports 20031001

• Medical treatment of vertebral osteoporosis.

  European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20031001

• Effects of long-term administration of N-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice.

  Journal of cellular biochemistry 20031001

• Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.

  Bone 20031001

• Nitrosation, nitration, and autoxidation of the selective estrogen receptor modulator raloxifene by nitric oxide, peroxynitrite, and reactive nitrogen/oxygen species.

  Chemical research in toxicology 20031001

• Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20031001

• A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials.

  Seminars in oncology 20031001

• DT56a stimulates creatine kinase specific activity in vascular tissues of rats.

  Journal of endocrinological investigation 20031001

• Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20030901

• Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells.

  The Journal of endocrinology 20030901

• Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women.

  The Journal of clinical endocrinology and metabolism 20030901

• Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.

  The Journal of clinical endocrinology and metabolism 20030901

• Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.

  Bone 20030901

• Effect of raloxifene on sexual function in postmenopausal women.

  Climacteric : the journal of the International Menopause Society 20030901

• Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease.

  Journal of the American College of Cardiology 20030820

• Synthesis and binding affinities of fluoroalkylated raloxifenes.

  Bioorganic & medicinal chemistry 20030815

• Early discontinuation of treatment for osteoporosis.

  The American journal of medicine 20030815

• [Osteoporosis therapy compared. More solid bones with bisphosphonates].

  MMW Fortschritte der Medizin 20030807

• [Treatment of osteoporosis].

  Orvosi hetilap 20030803

• Raloxifene analog LY117018 enhances the regeneration of sciatic nerve in ovariectomized female mice.

  Brain research 20030801

• Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells.

  The Journal of endocrinology 20030801

• Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.

  Chinese medical journal 20030801

• Review on raloxifene: profile of a selective estrogen receptor modulator.

  International journal of clinical pharmacology and therapeutics 20030801

• Synthesis of constrained raloxifene analogues by complementary use of Friedel-Crafts and directed remote metalation reactions.

  The Journal of organic chemistry 20030725

• Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?

  Lancet (London, England) 20030719

• Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation.

  The Journal of biological chemistry 20030718

• [Evidence-based assessment of therapeutic agents of osteoporosis. Bisphosphonates, SERM and basic therapy in front].

  MMW Fortschritte der Medizin 20030710

• Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.

  Journal of medicinal chemistry 20030703

• Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women.

  Clinical science (London, England : 1979) 20030701

• Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.

  Molecular endocrinology (Baltimore, Md.) 20030701

• New approaches to the endocrine prevention and treatment of breast cancer.

  Cancer chemotherapy and pharmacology 20030701

• Raloxifene, conjugated oestrogen and endothelial function in postmenopausal women.

  Journal of internal medicine 20030701

• Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women.

  The Journal of clinical endocrinology and metabolism 20030701

• Differential effects of unopposed versus opposed hormone therapy, tibolone, and raloxifene on substance p levels.

  Fertility and sterility 20030701

• The prevention of breast cancer.

  The British journal of surgery 20030701

• Short-term urogenital effects of raloxifene, tamoxifen, and estrogen.

  American journal of obstetrics and gynecology 20030701

• DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus.

  The Journal of steroid biochemistry and molecular biology 20030701

• The effects of raloxifene and simvastatin on plasma lipids and endothelium.

  Cardiovascular drugs and therapy 20030701

• Osteoporosis guidelines.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20030624

• Osteoporosis guidelines.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20030624

• [From alcohol abstinence to total surgery. Preventive strategies in breast carcinoma].

  MMW Fortschritte der Medizin 20030612

• [Hormone therapy, chemotherapy and immunotherapy in breast carcinoma. The best strategy for your patient].

  MMW Fortschritte der Medizin 20030612

• Raloxifene causing malabsorption of levothyroxine.

  Archives of internal medicine 20030609

• A novel estrogen receptor ligand template.

  Bioorganic & medicinal chemistry letters 20030602

• Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.

  Kidney international 20030601

• Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta.

  Journal of cellular biochemistry 20030601

• Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene.

  The Journal of endocrinology 20030601

• Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids.

  The Journal of clinical investigation 20030601

• Effect of raloxifene, 17beta-estradiol, and progesterone on mRNA for vascular endothelial growth factor isoforms 121 and 165 and thrombospondin-1 in Ishikawa cells.

  Fertility and sterility 20030601

• Effects of raloxifene therapy on the anticoagulant system in postmenopausal women.

  Climacteric : the journal of the International Menopause Society 20030601

• Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: levormeloxifene and raloxifene.

  Climacteric : the journal of the International Menopause Society 20030601

• Risk of fracture and treatment to prevent osteoporosis-related fracture in postmenopausal women. A review.

  The Journal of reproductive medicine 20030601

• Serum lipids and apolipoproteins in Greek postmenopausal women: association with estrogen, estrogen-progestin, tibolone and raloxifene therapy.

  Journal of endocrinological investigation 20030601

• Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat.

  Calcified tissue international 20030601

• Effects of estradiol, cyproterone acetate, tibolone and raloxifene on uterus and aorta atherosclerosis in oophorectomized cholesterol-fed rabbits.

  Maturitas 20030530

• [SERM for early osteoporosis therapy. Risk for first spinal fracture reduced to half].

  MMW Fortschritte der Medizin 20030529

• New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in ovariectomized rats.

  Endocrinology 20030501

• Endothelial function and menopause: effects of raloxifene administration.

  The Journal of clinical endocrinology and metabolism 20030501

• Administration of raloxifene does not influence 24-hour ambulatory blood pressure of postmenopausal women with osteopenia: a double-blind placebo-controlled study.

  American journal of obstetrics and gynecology 20030501

• Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women.

  Journal of the American Geriatrics Society 20030501

• Chemoprevention of breast cancer: recommendations and rationale.

  The American journal of nursing 20030501

• Differential effects of raloxifene, tamoxifen and fulvestrant on a murine mammary carcinoma.

  Breast cancer research and treatment 20030501

• Long-term toxicities of selective estrogen-receptor modulators and antiaromatase agents.

  Oncology (Williston Park, N.Y.) 20030501

• The effects of estrogen and raloxifene treatment on antioxidant enzymes in brain and liver of ovarectomized female rats.

  Endocrine research 20030501

• Selective estrogen-receptor modulators.

  Clinics in geriatric medicine 20030501

• Drugs in the news: an analysis of Canadian newspaper coverage of new prescription drugs.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20030429

• Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size.

  European journal of pharmacology 20030425

• [Rehabilitation in osteoporosis].

  Deutsche medizinische Wochenschrift (1946) 20030425

• Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor.

  Brain research. Molecular brain research 20030410

• [Untrustworthy criticism of an advertising brochure].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20030410

• De novo design, synthesis and evaluation of a non-steroidal diphenylnaphthyl propylene ligand for the estrogen receptor.

  Bioorganic & medicinal chemistry 20030403

• Raloxifene acts as an estrogen agonist on the rabbit growth plate.

  Endocrinology 20030401

• Raloxifene lowers IGF-I levels in acromegalic women.

  European journal of endocrinology 20030401

• Experts hopeful about designer estrogens. For some women, selective estrogen receptor modulators (SERMs) help prevent breast cancer.

  Health news (Waltham, Mass.) 20030401

• Adrenal function under long-term raloxifene administration.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20030401

• Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice.

  Neuroendocrinology 20030401

• [A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].

  Zhonghua fu chan ke za zhi 20030401

• [Breakthrough in breast cancer chemoprevention].

  Orvosi hetilap 20030330

• Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.

  Journal of medicinal chemistry 20030327

• Chemoprevention of breast cancer: recommendations and rationale.

  American family physician 20030315

• The effects of estrogen and raloxifene treatment on the antioxidant enzymes and nitrite-nitrate levels in brain cortex of ovariectomized rats.

  Neuroscience letters 20030306

• A homogeneous in vitro functional assay for estrogen receptors: coactivator recruitment.

  Molecular endocrinology (Baltimore, Md.) 20030301

• Effects of raloxifene on carotid blood flow resistance and endothelium-dependent vasodilation in postmenopausal women.

  Atherosclerosis 20030301

• Anti-oestrogenic chemoprevention of breast cancer-the need to progress.

  European journal of cancer (Oxford, England : 1990) 20030301

• Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism.

  The Journal of clinical endocrinology and metabolism 20030301

• Selective estrogen receptors modulators in the prevention and treatment of postmenopausal osteoporosis.

  Endocrinology and metabolism clinics of North America 20030301

• [SERMs and uterus].

  Annales de medecine interne 20030301

• Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.

  Clinical therapeutics 20030301

• Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.

  The Journal of biological chemistry 20030227

• [Diabetes, Conn syndrome and osteoporosis. What is new in diagnosis and therapy?].

  MMW Fortschritte der Medizin 20030227

• Application of breast cancer risk prediction models in clinical practice.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030215

• Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

  The New England journal of medicine 20030213

• 2-Phenylspiroindenes: a novel class of selective estrogen receptor modulators (SERMs).

  Bioorganic & medicinal chemistry letters 20030210

• Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women.

  Fertility and sterility 20030201

• Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy.

  Obstetrics and gynecology 20030201

• Effect of raloxifene on sexual function in older postmenopausal women with osteoporosis.

  Obstetrics and gynecology 20030201

• Comparison of the effect of oestradiol, tamoxifen and raloxifene on nerve growth factor-alpha expression in specific neonatal mouse uterine cell types using laser capture microdissection.

  Journal of molecular endocrinology 20030201

• Raloxifene and endothelial function in healthy postmenopausal women.

  American journal of obstetrics and gynecology 20030201

• Raloxifene does not influence flow-mediated endothelium-dependent and endothelium-independent vasodilatation of osteopenic postmenopausal women.

  American journal of obstetrics and gynecology 20030201

• Comparison of the effect of raloxifene and continuous-combined hormone therapy on mammographic breast density and breast tenderness in postmenopausal women.

  American journal of obstetrics and gynecology 20030201

• [The therapy of endometriosis. New prospects].

  Minerva ginecologica 20030201

• A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.

  BJOG : an international journal of obstetrics and gynaecology 20030201

• [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].

  Recenti progressi in medicina 20030201

• Overview of the main outcomes in breast-cancer prevention trials.

  Lancet (London, England) 20030125

• [Absolutely not true and relatively true about risk reduction].

  Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20030109

• The hidden alternative: getting investigational treatments off-study.

  Lancet (London, England) 20030104

• Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells.

  Endocrinology 20030101

• Biological significance of interventions that change breast density.

  Journal of the National Cancer Institute 20030101

• Growth effects of raloxifene, estradiol, medroxy-progesterone acetate, and progesterone on human endometrial adenocarcinoma cells.

  Fertility and sterility 20030101

• Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes.

  Human reproduction (Oxford, England) 20030101

• National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20030101

• Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women.

  Menopause (New York, N.Y.) 20030101

• [The current state of hormonal prevention of coronary heart disease in menopausal women].

  Revista espanola de cardiologia 20030101

• Raloxifene to prevent cardiovascular disease? Don't use it yet!

  Menopause (New York, N.Y.) 20030101

• Raloxifene is a better antioxidant of low-density lipoprotein than estradiol or tamoxifen in postmenopausal women in vitro.

  Menopause (New York, N.Y.) 20030101

• Effects of bilateral ovariectomy and postoperative hormonal replacement therapy with 17beta-estradiol or raloxifene on serum leptin levels.

  Menopause (New York, N.Y.) 20030101

• Lack of hormonal influences on mechanical properties of sheep knee ligaments.

  The American journal of sports medicine 20030101

• Prevention and early detection clinical trials: opportunities for primary care providers and their patients.

  CA: a cancer journal for clinicians 20030101

• Gender, hyperlipidemia, and coronary artery disease.

  Comprehensive therapy 20030101

• Effects of SERM (selective estrogen receptor modulator) treatment on growth and proliferation in the rat uterus.

  Reproductive biology and endocrinology : RB&E 20030101

• Counseling patients who elect to discontinue hormone therapy.

  International journal of fertility and women's medicine 20030101

• Therapeutic options: an evidence-based approach to prevention and treatment of osteoporosis.

  International journal of fertility and women's medicine 20030101

• Treatment of osteoporosis: combination therapies.

  International journal of fertility and women's medicine 20030101

• Direct-to-consumer marketing of osteoporosis drugs and bone densitometry.

  The Annals of pharmacotherapy 20030101

• Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.

  Menopause (New York, N.Y.) 20030101

• Conformational sampling by self-organization.

  Journal of chemical information and computer sciences 20030101

• Growth response of colon cancer cell lines to selective estrogen receptor modulators.

  Anticancer research 20030101

• [Perspectives for the hormonal therapy of breast cancer].

  Magyar onkologia 20030101

• Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women.

  International journal of tissue reactions 20030101

• Effects of estrogen and raloxifene on neuroglia number and morphology in the hippocampus of aged female mice.

  Neuroscience 20030101

• beta-estradiol influences differentiation of hippocampal neurons in vitro through an estrogen receptor-mediated process.

  Neuroscience 20030101

• Effects of an isopropanolic extract of Cimicifuga racemosa on urinary crosslinks and other parameters of bone quality in an ovariectomized rat model of osteoporosis.

  Journal of bone and mineral metabolism 20030101

• Prevention of breast cancer using SERMs and aromatase inhibitors.

  Journal of mammary gland biology and neoplasia 20030101

• Diagnosing and managing post menopausal osteoporosis: opportunities for fracture prevention.

  Comprehensive therapy 20030101

• Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene.

  Tumori 20030101

• Case report: raloxifene in postmenopausal women with psychosis: preliminary findings.

  The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 20030101

• Modeling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy.

  Journal of managed care pharmacy : JMCP 20030101

• ERT, HRT, raloxifine, calcitonin, or bisphosphonates for osteoporosis.

  Journal of managed care pharmacy : JMCP 20030101

• Influence of tacrolimus and short-duration prednisone on bone mineral density following liver transplantation.

  JPEN. Journal of parenteral and enteral nutrition 20030101

• [Treatment of postmenopausal osteoporosis].

  Anales del sistema sanitario de Navarra 20030101

• [Drugs prescription for osteoporosis].

  Anales del sistema sanitario de Navarra 20030101

• [The role of raloxifene (Evista) in the treatment and prevention of postmenopausal osteoporosis].

  Reumatizam 20030101

• Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment.

  Advances in experimental medicine and biology 20030101

• Effect of raloxifene on lowering lipid parameters in patients with osteoporosis.

  International journal of clinical pharmacology research 20030101

• Risk-reducing strategies for breast cancer--a review of recent literature.

  International journal of fertility and women's medicine 20030101

• Hip fracture patients are not treated for osteoporosis: a call to action.

  Arthritis and rheumatism 20021215

• Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial.

  The American journal of cardiology 20021201

• Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial.

  Human reproduction (Oxford, England) 20021201

• Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20021201

• Medications for postmenopausal osteoporosis prevention.

  Harvard women's health watch 20021201

• Differential effects of selective estrogen receptor modulators and estrogens on mammary blood flow in the ovine.

  American journal of obstetrics and gynecology 20021201

• ACOG practice bulletin. Selective estrogen receptor modulators. Number 39, October 2002 (replaces Committee Opinion Number 224, October 1999).

  International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 20021201

• [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis].

  Minerva medica 20021201

• [Osteoporosis].

  Der Internist 20021201

• [Osteoporosis].

  Ryumachi. [Rheumatism] 20021201

• Rapid effects of estrogen on G protein-coupled receptor activation of potassium channels in the central nervous system (CNS).

  The Journal of steroid biochemistry and molecular biology 20021201

• Antiestrogens: the past and the future.

  Zentralblatt fur Gynakologie 20021201

• [Treatments of Osteoporosis with SERM and their EBM].

  Clinical calcium 20021201

• [Rationale for the treatment of postmenopausal women by SERM].

  Clinical calcium 20021201

• [Osteoporosis: prevention of bone loss and fractures].

  MMW Fortschritte der Medizin 20021128

• Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.

  The Journal of biological chemistry 20021122

• Tamoxifen versus raloxifene in the prevention of breast cancer.

  European journal of cancer (Oxford, England : 1990) 20021101

• An update on non-uterine gynaecological effects on raloxifene.

  European journal of cancer (Oxford, England : 1990) 20021101

• The role of estrogens and related compounds in the management of primary hyperparathyroidism.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20021101

• Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20021101

• Bioidentical hormone replacement therapy. Customizing care for perimenopausal and menopausal women.

  Advance for nurse practitioners 20021101

• Drugs for prevention and treatment of postmenopausal osteoporosis.

  Treatment guidelines from the Medical Letter 20021101

• [Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].

  MMW Fortschritte der Medizin 20021031

• Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.

  Bioorganic & medicinal chemistry letters 20021021

• [Do markers of bone metabolism reflect the presence of a high- or low-turnover state of bone metabolism?].

  Medizinische Klinik (Munich, Germany : 1983) 20021015

• Pharmacological actions of a novel, potent, tissue-selective benzopyran estrogen.

  The Journal of pharmacology and experimental therapeutics 20021001

• Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells.

  Molecular pharmacology 20021001

• Raloxifene administration in women treated with gonadotropin-releasing hormone agonist for uterine leiomyomas: effects on bone metabolism.

  The Journal of clinical endocrinology and metabolism 20021001

• Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women.

  European journal of endocrinology 20021001

• Responsiveness of endometrial genes Connexin26, Connexin43, C3 and clusterin to primary estrogen, selective estrogen receptor modulators, phyto- and xenoestrogens.

  Journal of molecular endocrinology 20021001

• Endometriosis: novel etiopathogenetic concepts and clinical perspectives.

  Fertility and sterility 20021001

• ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists: Number 39, October 2002. Selective estrogen receptor modulators.

  Obstetrics and gynecology 20021001

• Task force cautious about chemoprevention. Official guidelines are out about taking tamoxifen and raloxifene to prevent breast cancer. These drugs can help, but they aren't for everyone.

  Harvard women's health watch 20021001

• Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain.

  Neuroendocrinology 20021001

• Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.

  Cancer research 20020915

• [Specific estrogen receptor modulators (SERMs)].

  Presse medicale (Paris, France : 1983) 20020907

• Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells.

  The Journal of biological chemistry 20020906

• Raloxifene effects upon the neuronal system controlling sexual receptivity in female rats.

  Neuroscience letters 20020906

• Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart.

  Journal of the American College of Cardiology 20020904

• Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women.

  The Journal of clinical endocrinology and metabolism 20020901

• The effect of raloxifene on glyco-insulinemic homeostasis in healthy postmenopausal women: a randomized placebo-controlled study.

  The Journal of clinical endocrinology and metabolism 20020901

• Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity.

  Fertility and sterility 20020901

• Osteoporosis.

  Postgraduate medical journal 20020901

• Breast cancer prevention and surveillance.

  Clinical obstetrics and gynecology 20020901

• The Study of Tamoxifen and Raloxifene (STAR trial) for the prevention of breast cancer.

  Hawaii medical journal 20020901

• American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20020801

• Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.

  Cancer research 20020801

• Raloxifene administration in premenopausal women with uterine leiomyomas: a pilot study.

  The Journal of clinical endocrinology and metabolism 20020801

• Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.

  The Journal of clinical endocrinology and metabolism 20020801

• Improvement in the undertreatment of osteoporosis following hip fracture.

  The Journal of bone and joint surgery. American volume 20020801

• A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life.

  BJOG : an international journal of obstetrics and gynaecology 20020801

• Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis.

  Endocrine reviews 20020801

• Estrogen and selective estrogen receptor modulator regulation of insulin-like growth factor binding protein 5 in the rat uterus.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20020801

• Tamoxifen and raloxifene may benefit women at high risk for breast cancer.

  Report on medical guidelines & outcomes research 20020726

• [CBO guideline 'Osteoporosis' (second revision].

  Nederlands tijdschrift voor geneeskunde 20020720

• USPSTF releases guidelines on breast-cancer chemoprevention.

  Lancet (London, England) 20020706

• Raloxifene and risk of cardiovascular events.

  JAMA 20020703

• Chemoprevention of breast cancer: recommendations and rationale.

  Annals of internal medicine 20020702

• Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.

  Annals of internal medicine 20020702

• Summaries for patients. Using medication to prevent breast cancer: recommendations from the United States Preventive Services Task Force.

  Annals of internal medicine 20020702

• Estrogen receptor alpha inhibits IL-1beta induction of gene expression in the mouse liver.

  Endocrinology 20020701

• Raloxifene, a selective estrogen receptor modulator, induces apoptosis in androgen-responsive human prostate cancer cell line LNCaP through an androgen-independent pathway.

  Cancer research 20020701

• Raloxifene: recent information on skeletal and non-skeletal effects.

  Current opinion in rheumatology 20020701

• Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation.

  Chemical research in toxicology 20020701

• [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist].

  Ceska gynekologie 20020701

• Differential interactions of estrogens and antiestrogens at the 17 beta-hydroxyl or counterpart hydroxyl with histidine 524 of the human estrogen receptor alpha.

  Biochemistry 20020625

• Tamoxifen, raloxifene and the prevention of breast cancer.

  Minerva endocrinologica 20020601

• Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.

  Drug metabolism and disposition: the biological fate of chemicals 20020601

• The search for the ideal SERM.

  Expert opinion on pharmacotherapy 20020601

• Review of raloxifene and its clinical applications in osteoporosis.

  Expert opinion on pharmacotherapy 20020601

• Raloxifene and cardiovascular disease.

  Climacteric : the journal of the International Menopause Society 20020601

• Transvaginal color Doppler sonographic evaluation of the uterus in postmenopausal women on daily raloxifene therapy.

  Climacteric : the journal of the International Menopause Society 20020601

• Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells.

  Gynecologic oncology 20020601

• Raloxifene treatment increases plasma levels of beta-endorphin in postmenopausal women: a randomized, placebo-controlled study.

  Fertility and sterility 20020601

• Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20020601

• [Antiestrogen therapy in the treatment of breast neoplasms].

  Minerva ginecologica 20020601

• 6-Carboxymethyl genistein: a novel selective oestrogen receptor modulator (SERM) with unique, differential effects on the vasculature, bone and uterus.

  The Journal of endocrinology 20020601

• Use of alternative therapies in menopause.

  Best practice & research. Clinical obstetrics & gynaecology 20020601

• Breast pain and mammographic density increase as a consequence of raloxifene therapy.

  Journal of endocrinological investigation 20020601

• The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.

  Clinical breast cancer 20020601

• A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.

  Seminars in oncology 20020601

• The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review.

  Neuropsychology review 20020601

• Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis.

  Archives of internal medicine 20020527

• [From effective to economical. The value of good osteoporosis therapy].

  MMW Fortschritte der Medizin 20020523

• Mood effect of raloxifene in postmenopausal women.

  Maturitas 20020520

• Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women.

  Maturitas 20020520

• Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.

  International journal of cancer 20020510

• [Can serum estradiol predict the effect of raloxifene on breast cancer risk?].

  Lakartidningen 20020502

• Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques.

  Psychoneuroendocrinology 20020501

• The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women.

  Gynecologic oncology 20020501

• Mechanism of raloxifene-induced relaxation in femoral veins depends on ovarian hormonal status.

  Journal of cardiovascular pharmacology 20020501

• Effect of raloxifene on the ovarian circulation in women after menopause.

  American journal of obstetrics and gynecology 20020501

• Effects of hormones on uPA, PAI-1 and suPAR from cultured endometrial and ovarian endometriotic stromal cells.

  Acta obstetricia et gynecologica Scandinavica 20020501

• Menopause. HRT: looking for something better.

  Harvard health letter 20020501

• Cardiovascular effects of raloxifene: the potential for cardiovascular protection in women.

  Diabetes, obesity & metabolism 20020501

• Pharmacotherapy of osteoporosis in postmenopausal women: focus on safety.

  Expert opinion on drug safety 20020501

• Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production.

  Circulation 20020430

• Growth-stimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells.

  Molecular and cellular endocrinology 20020425

• A 60-year-old woman trying to discontinue hormone replacement therapy.

  JAMA 20020424

• [Current therapeutic means].

  Presse medicale (Paris, France : 1983) 20020420

• Upstaging tamoxifen? New classes of drugs emerging for breast cancer.

  Journal of the National Cancer Institute 20020403

• Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women.

  Bone 20020401

• Identifying and counseling women at increased risk for breast cancer.

  Mayo Clinic proceedings 20020401

• Environmental fate and chemistry of raloxifene hydrochloride.

  Environmental toxicology and chemistry 20020401

• Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.

  American journal of obstetrics and gynecology 20020401

• Effects of the selective estrogen receptor modulator, raloxifene, on carotid artery pulsatility index in postmenopausal women.

  American journal of obstetrics and gynecology 20020401

• Raloxifene is associated with less side effects than tamoxifen in women with early breast cancer: a questionnaire study from one physician's practice.

  Journal of women's health & gender-based medicine 20020401

• Efficacy of raloxifene for treatment of menopause: a systematic review.

  Journal of the American Academy of Nurse Practitioners 20020401

• Raloxifene remains an option.

  Canadian family physician Medecin de famille canadien 20020401

• [Rational and cost effective osteoporosis prevention and therapy].

  Der Internist 20020401

• The controversy over estrogen replacement therapy: an update on clinical trials.

  Current women's health reports 20020401

• Biomedicine. Defining the 'S' in SERMs.

  Science (New York, N.Y.) 20020329

• Molecular determinants for the tissue specificity of SERMs.

  Science (New York, N.Y.) 20020329

• Measurement of serum estradiol.

  JAMA 20020327

• Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene.

  Circulation 20020319

• Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.

  The Journal of biological chemistry 20020315

• Hormone replacement therapy trials: an update.

  Current atherosclerosis reports 20020301

• A synthetic peptide with estrogen-like activity derived from a phage-display peptide library.

  Peptides 20020301

• Raloxifene revisited.

  Fertility and sterility 20020301

• Estradiol down-regulates MCP-1 expression in human coronary artery endothelial cells.

  Fertility and sterility 20020301

• Comparative effects of testosterone propionate, oestradiol benzoate, ICI 182,780, tamoxifen and raloxifene on hypothalamic differentiation in the female rat.

  The Journal of endocrinology 20020301

• Inhibition of intimal hyperplasia using the selective estrogen receptor modulator raloxifene.

  Archives of surgery (Chicago, Ill. : 1960) 20020301

• For osteoporosis, are two antiresorptive drugs better than one?

  The Journal of clinical endocrinology and metabolism 20020301

• Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis.

  The Journal of clinical endocrinology and metabolism 20020301

• Hormone may be key to raloxifene's breast cancer benefits.

  Health news (Waltham, Mass.) 20020301

• Molecular simulation of interaction between estrogen receptor and selective estrogen receptor modulators.

  Acta pharmacologica Sinica 20020301

• Therapeutic interventions in osteoporosis.

  Nursing times 20020301

• [Advancement of treatment for osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20020301

• [Treatment of osteoporosis: overview].

  Nihon rinsho. Japanese journal of clinical medicine 20020301

• [Comparative analyses on osteoporosis guidelines in Japan, EU and USA].

  Nihon rinsho. Japanese journal of clinical medicine 20020301

• [Advance in the treatment of postmenopausal osteoporosis].

  Nihon rinsho. Japanese journal of clinical medicine 20020301

• [Drugs in development for the treatment of osteoporosis:Raloxifene].

  Nihon rinsho. Japanese journal of clinical medicine 20020301

• [Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated].

  MMW Fortschritte der Medizin 20020227

• A 2-year, randomized, comparative, placebo-controlled study on the effects of raloxifene on lipoprotein(a) and homocysteine.

  Maturitas 20020226

• Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.

  JAMA 20020220

• Hobson's choice and the need for combinations of new agents for the prevention and treatment of breast cancer.

  Journal of the National Cancer Institute 20020220

• Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice.

  Journal of the National Cancer Institute 20020220

• Estrogen replacement therapy, atherosclerosis, and vascular function.

  Cardiovascular research 20020215

• Role of antiestrogens and aromatase inhibitors in breast cancer treatment.

  Current opinion in obstetrics & gynecology 20020201

• Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer.

  Current opinion in obstetrics & gynecology 20020201

• Bone histomorphometric and biochemical marker results of a 2-year placebo-controlled trial of raloxifene in postmenopausal women.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20020201

• Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.

  Trends in molecular medicine 20020201

• The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro.

  Bone 20020201

• Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20020201

• Recruitment of women into trials.

  Lancet (London, England) 20020112

• Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression.

  European journal of pharmacology 20020111

• Serum estradiol level and risk of breast cancer during treatment with raloxifene.

  JAMA 20020109

• Teasing out effects of estrogen on the brain.

  JAMA 20020102

• Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20020101

• Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20020101

• Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial.

  The Journal of clinical endocrinology and metabolism 20020101

• Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats.

  Bone 20020101

• Selective estrogen receptor modulator effects in the rat brain.

  Neuroendocrinology 20020101

• Breast cancer risk reduction: strategies for women at increased risk.

  Annual review of medicine 20020101

• [Amelioration of ischemia- and reperfusion-induced myocardial injury by the selective estrogen receptor modulator, raloxifene, in the canine heart].

  Journal of cardiology 20020101

• Breast cancer prevention.

  The oncologist 20020101

• Effects of the environmental estrogens bisphenol A, o,p'-DDT, p-tert-octylphenol and coumestrol on apoptosis induction, cell proliferation and the expression of estrogen sensitive molecular parameters in the human breast cancer cell line MCF-7.

  The Journal of steroid biochemistry and molecular biology 20020101

• Hormone replacement therapy and breast tissue density on mammography.

  Menopause (New York, N.Y.) 20020101

• Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study.

  Menopause (New York, N.Y.) 20020101

• Toxicity of antiestrogens.

  The breast journal 20020101

• Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade.

  Clinical breast cancer 20020101

• Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.

  Environmental and molecular mutagenesis 20020101

• Chemoprevention of breast cancer: implications for postmenopausal women.

  Drugs & aging 20020101

• Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures.

  European cytokine network 20020101

• Estradiol, but not raloxifene, improves aspects of spatial working memory in aged ovariectomized rhesus monkeys.

  Neurobiology of aging 20020101

• Sequence- and time-dependent antagonism between raloxifene and methotrexate in human breast cancer cells.

  Anticancer research 20020101

• Response of bone mineral density to once-weekly administration of risedronate.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101

• The hemorheological effects of raloxifene in postmenopausal women with osteoporosis. Results of a 3-year placebo-controlled clinical trial.

  Clinical hemorheology and microcirculation 20020101

• Serum placental protein 14: a novel marker of selective oestrogen receptor modulator action on the postmenopausal endometrium.

  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20020101

• Development of cross-resistance to tamoxifen in raloxifene-treated breast carcinoma cells.

  Anticancer research 20020101

• Similarity of uterine mucosa changes in patients treated by raloxifen and tamoxifen.

  Anticancer research 20020101

• [Selective estrogen receptor modulators (SERMs) in the practice].

  Magyar onkologia 20020101

• How does raloxifene reduce fracture risk?

  Menopause (New York, N.Y.) 20020101

• Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys.

  Menopause (New York, N.Y.) 20020101

• Selective estrogen receptor modulators: tissue actions and potential for CNS protection.

  CNS drug reviews 20020101

• Jumping exercises with and without raloxifene treatment in healthy elderly women.

  Journal of bone and mineral metabolism 20020101

• Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women.

  Medscape women's health 20020101

• A review of combination regimens for osteoporosis--prevention and treatment.

  International journal of fertility and women's medicine 20020101

• [Osteoporosis: diagnosis, prevention and treatment].

  Medicina (Kaunas, Lithuania) 20020101

• Vascular effects of raloxifene in post-menopausal women.

  Journal of endocrinological investigation 20020101

• Raloxifene and pituitary secretion in post-menopausal women.

  Journal of endocrinological investigation 20020101

• Chemoprevention of breast cancer: current and future prospects.

  Cancer metastasis reviews 20020101

• [Osteoporosis].

  Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 20020101

• Activity of a tamoxifen-raloxifene hybrid ligand for estrogen receptors at an AP-1 site.

  Bioorganic & medicinal chemistry letters 20011217

• Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells.

  The Journal of biological chemistry 20011214

• Raloxifene.

  Current drug targets 20011201

• Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.

  British journal of cancer 20011201

• Cost-effectiveness of raloxifene and hormone replacement therapy in postmenopausal women: impact of breast cancer risk.

  Obstetrics and gynecology 20011201

• Spontaneous reports of pulmonary embolism in association with raloxifene.

  Obstetrics and gynecology 20011201

• Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review.

  Climacteric : the journal of the International Menopause Society 20011201

• Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.

  Climacteric : the journal of the International Menopause Society 20011201

• Effects of phytoestrogens on DNA synthesis and creatine kinase activity in vascular cells.

  American journal of hypertension 20011201

• [What do we think about selective estrogen receptor modulators?].

  La Revue de medecine interne 20011201

• A brief review of the International Breast Cancer Intervention Study (IBIS), the other current breast cancer prevention trials, and proposals for future trials.

  Annals of the New York Academy of Sciences 20011201

• The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.

  Annals of the New York Academy of Sciences 20011201

• The effects of estrogen and selective estrogen receptor modulators on cardiovascular risk factors.

  Annals of the New York Academy of Sciences 20011201

• Selective estrogen receptor modulator effects on serum lipoproteins and vascular function in postmenopausal women and in hypercholesterolemic men.

  Annals of the New York Academy of Sciences 20011201

• Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial.

  Annals of the New York Academy of Sciences 20011201

• Preventing and treating osteoporosis: strategies at the millennium.

  Annals of the New York Academy of Sciences 20011201

• The paradox of small changes in bone density and reductions in risk of fracture with raloxifene.

  Annals of the New York Academy of Sciences 20011201

• The effect of SERMs on the endometrium.

  Annals of the New York Academy of Sciences 20011201

• Raloxifene: risks and benefits.

  Annals of the New York Academy of Sciences 20011201

• The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1).

  Annals of the New York Academy of Sciences 20011201

• Chemoprevention with antiestrogens: the beginning of the end for breast cancer. Daniel G. Miller Lecture.

  Annals of the New York Academy of Sciences 20011201

• Changes in biochemical markers of bone turnover in women treated with raloxifene: influence of regression to the mean.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20011201

• Raloxifene versus continuous combined estrogen/progestin therapy: densitometric and biochemical effects in healthy postmenopausal Taiwanese women.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20011201

• [The effect of raloxifene on bone tissue in postmenopausal women].

  Polskie Archiwum Medycyny Wewnetrznej 20011201

• [Risk-adapted therapy of osteoporosis. Preventing fractures].

  MMW Fortschritte der Medizin 20011122

• [Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].

  MMW Fortschritte der Medizin 20011122

• The tamoxifen-responsive estrogen receptor alpha mutant D351Y shows reduced tamoxifen-dependent interaction with corepressor complexes.

  The Journal of biological chemistry 20011116

• Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20011101

• The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study.

  Arthritis and rheumatism 20011101

• The role of serial bone mineral density testing for osteoporosis.

  Journal of women's health & gender-based medicine 20011101

• Breast cancer chemoprevention: current clinical practice and future direction.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20011101

• Evidence for an estrogen-like action of raloxifene upon the hypothalamic-pituitary unit: raloxifene inhibits luteinizing hormone secretion and stimulates prolactin secretion in ovariectomized female rats.

  Neuroscience letters 20011005

• Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.

  Journal of the National Cancer Institute 20011003

• Raloxifene and breast cancer.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20011002

• Transcriptional activities of estrogen receptor alpha and beta in yeast properties of raloxifene.

  Biochemical pharmacology 20011001

• Effects of long-term use of raloxifene, a selective estrogen receptor modulator, on thyroid function test profiles.

  Clinical chemistry 20011001

• Role of tumor necrosis factor-alpha and interleukin-6 in the effects of hormone replacement therapy and raloxifene on C-reactive protein in postmenopausal women.

  The American journal of cardiology 20011001

• Patterns of physician-reported diagnoses for women receiving raloxifene prescriptions.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20011001

• Identification of a mutation in the human raloxifene response element of the transforming growth factor-beta 3 gene.

  Journal of Korean medical science 20011001

• Does raloxifene reduce risk of vertebral fractures? Is this another, brighter way to treat osteoporosis?

  Canadian family physician Medecin de famille canadien 20011001

• Neuroendocrine effects of raloxifene hydrochloride in postmenopausal women.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20011001

• Breast cancer prevention: present and future.

  Cancer treatment reviews 20011001

• Raloxifene for the treatment and prevention of breast cancer?

  Expert review of anticancer therapy 20011001

• Evaluation and treatment of postmenopausal osteoporosis.

  The American journal of managed care 20010925

• Risk-reduction mastectomy: clinical issues and research needs.

  Journal of the National Cancer Institute 20010905

• Comparisons of the effects of tamoxifen, toremifene and raloxifene on enzyme induction and gene expression in the ovariectomised rat uterus.

  The Journal of endocrinology 20010901

• Pharmacologic therapy for the treatment and prevention of osteoporosis.

  The Nursing clinics of North America 20010901

• Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.

  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20010901

• Induction of the progesterone receptor gene in estrogen target cells monitored by branched DNA signal amplification.

  Steroids 20010901

• Influence of smoking on the antiosteoporotic efficacy of raloxifene.

  The Journal of clinical endocrinology and metabolism 20010901

• Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma no concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women.

  Arteriosclerosis, thrombosis, and vascular biology 20010901

• Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study.

  American journal of obstetrics and gynecology 20010901

• 1-(2-[4-[6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiol-3-ylcarbonyl]phenoxy]ethyl)piperidinium chloride.

  Acta crystallographica. Section C, Crystal structure communications 20010901

• Selective estrogen-receptor modulators in 2001.

  Oncology (Williston Park, N.Y.) 20010901

• Effect of raloxifene on serum triglycerides in postmenopausal women: influence of predisposing factors for hypertriglyceridemia.

  Clinical therapeutics 20010901

• [New drugs].

  Revue medicale de Bruxelles 20010901

• Breast cancer prevention.

  Clinical obstetrics and gynecology 20010901

• Update in general internal medicine.

  Annals of internal medicine 20010821

• Design and methods of the Raloxifene Use for The Heart (RUTH) study.

  The American journal of cardiology 20010815

• Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice.

  Synapse (New York, N.Y.) 20010801

• Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain.

  Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 20010801

• Familiar drugs may prevent cancer.

  Postgraduate medical journal 20010801

• Bone builders: preventing and treating osteoporosis.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010801

• Bone builders: the discoveries behind preventing and treating osteoporosis.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20010801

• Adenomyosis--a result of disordered stromal differentiation.

  The American journal of pathology 20010801

• Raloxifene-mediated increase in matrix metalloproteinase-1 production by activated monocytes.

  Arteriosclerosis, thrombosis, and vascular biology 20010801

• Multiplexed molecular interactions of nuclear receptors using fluorescent microspheres.

  Cytometry 20010801

• Molecular identification of potential selective estrogen receptor modulator (SERM) like properties of phytoestrogens in the human breast cancer cell line MCF-7.

  Planta medica 20010801

• Lack of substantial effects of raloxifene on thyroxine-binding globulin in postmenopausal women: dependency on thyroid status.

  Thyroid : official journal of the American Thyroid Association 20010801

• Homocysteine in postmenopausal women and the importance of hormone replacement therapy.

  Clinical chemistry and laboratory medicine 20010801

• Raloxifene encourages growth of ovarian cancer cells in vitro news.

  The Lancet. Oncology 20010801

• Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women.

  Maturitas 20010725

• Raloxifene: handle with care.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20010724

• 2-Amino-4,6-diarylpyridines as novel ligands for the estrogen receptor.

  Bioorganic & medicinal chemistry letters 20010723

• Rheumatology: 15. Osteoporosis.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20010710

• Tamoxifen and contralateral breast cancer: the other side.

  Journal of the National Cancer Institute 20010704

• Gonadotropins at menopause: the influence of obesity, insulin resistance, and estrogens.

  Steroids 20010701

• Raloxifene effect on frequency of surgery for pelvic floor relaxation.

  Obstetrics and gynecology 20010701

• Effects of raloxifene treatment on uterine leiomyomas in postmenopausal women.

  Fertility and sterility 20010701

• Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin.

  Pharmaceutical research 20010701

• [Hormone replacement and selective estrogen receptor modulators (SERMS) in the prevention and treatment of postmenopausal osteoporosis].

  Der Orthopade 20010701

• Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010615

• Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20010612

• Oestrogenic effects of neonatal administration of raloxifene on hypothalamic-pituitary-gonadal axis in male and female rats.

  Reproduction (Cambridge, England) 20010601

• Effect of physicians opinion on patients' choice of treatment.

  European journal of obstetrics, gynecology, and reproductive biology 20010601

• Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.

  The Journal of clinical endocrinology and metabolism 20010601

• Breast cancer chemoprevention: current status and future directions.

  Seminars in oncology 20010601

• Tamoxifen to raloxifene and beyond.

  Seminars in oncology 20010601

• Osteoporosis.

  Tennessee medicine : journal of the Tennessee Medical Association 20010601

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference.

  Southern medical journal 20010601

• Medication update.

  Southern medical journal 20010601

• Estrogenic and antiestrogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells.

  Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20010601

• Tamoxifen, screening and new oestrogen receptor modulators.

  Best practice & research. Clinical obstetrics & gynaecology 20010601

• Flexible alignment of small molecules.

  Journal of medicinal chemistry 20010510

• Effect of tibolone and raloxifene on the tail temperature of oestrogen-deficient rats.

  European journal of pharmacology 20010504

• Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.

  Cancer research 20010501

• Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000.

  Fertility and sterility 20010501

• Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites.

  Chemistry & biology 20010501

• Effects of the selective oestrogen receptor modulator-raloxifene-on calcium and PTH secretory dynamics in women with osteoporosis.

  Clinical endocrinology 20010501

• Raloxifene for breast cancer prevention.

  JAMA 20010425

• Raloxifene fails to slow cognitive decline in older women.

  Lancet (London, England) 20010421

• Cognitive function in postmenopausal women treated with raloxifene.

  The New England journal of medicine 20010419

• Can estrogen or selective estrogen-receptor modulators preserve cognitive function in elderly women?

  The New England journal of medicine 20010419

• [SERM--selective estrogen receptor modulators].

  Ugeskrift for laeger 20010409

• Suggested rationale for prevention and treatment of glucocorticoid-induced bone loss in dermatologic patients.

  Archives of dermatology 20010401

• [An alternative to postmenopausal Hormone Replacement Therapy? Selective Estrogens Receptors Modulators (SERMs)].

  Minerva ginecologica 20010401

• Estrogenic activity of tamoxifen and raloxifene on rat brain AMPA receptors.

  Neuroreport 20010305

• A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.

  The Journal of clinical endocrinology and metabolism 20010301

• Raloxifene affects brain activation patterns in postmenopausal women during visual encoding.

  The Journal of clinical endocrinology and metabolism 20010301

• Managing menopause after breast cancer: balancing risks and benefits.

  Cleveland Clinic journal of medicine 20010301

• Comparative safety of bone remodeling agents with a focus on osteoporosis therapies.

  Journal of clinical pharmacology 20010301

• Therapy for osteoporosis.

  Journal of the South Carolina Medical Association (1975) 20010301

• SERMs and cardiovascular disease in women. How do these agents affect risk?

  Postgraduate medicine 20010301

• Selective estrogen receptor modulators. An aid in unraveling the links between estrogen and breast cancer.

  Postgraduate medicine 20010301

• Osteoporosis therapies for rheumatoid arthritis patients: minimizing gastrointestinal side effects.

  Seminars in arthritis and rheumatism 20010201

• Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.

  American journal of obstetrics and gynecology 20010201

• The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis.

  Rheumatic diseases clinics of North America 20010201

• An update on glucocorticoid-induced osteoporosis.

  Rheumatic diseases clinics of North America 20010201

• [SERM-therapy in postmenopause. Protection of bone and breast].

  MMW Fortschritte der Medizin 20010125

• Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing.

  Journal of the National Cancer Institute 20010103

• Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo.

  Journal of the National Cancer Institute 20010103

• Raloxifene and estrogen reduces progression of advanced atherosclerosis--a study in ovariectomized, cholesterol-fed rabbits.

  Atherosclerosis 20010101

• Hormones and the brain: more studies.

  Harvard women's health watch 20010101

• Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.

  Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20010101

• Estrogen and raloxifene activities on amyloid-beta-induced inflammatory reaction.

  Microvascular research 20010101

• Drug information needs clarification.

  Canadian family physician Medecin de famille canadien 20010101

• Chemoprevention of breast cancer.

  Southern medical journal 20010101

• Chemoprevention of breast cancer.

  Cancer treatment and research 20010101

• Breast cancer prevention study aims to overcome drug bias.

  JAMA 20010101

• [Prevention of breast cancer--what are the latest developments?].

  Harefuah 20010101

• Breast cancer chemoprevention: beyond tamoxifen.

  Breast cancer research : BCR 20010101

• Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.

  Breast cancer research and treatment 20010101

• The prevention of breast cancer: an overview.

  Current medical research and opinion 20010101

• Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function.

  Women's health issues : official publication of the Jacobs Institute of Women's Health 20010101

• Raloxifene.

  Journal of bone and mineral metabolism 20010101

• Regression to the mean: what does it mean? Using bone density results to monitor treatment of osteoporosis.

  Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 20010101

• Cardiovascular effects of raloxifene hydrochloride.

  Cardiovascular drug reviews 20010101

• Prevention and treatment of osteoporosis.

  Clinical medicine (London, England) 20010101

• Initiation of osteoporosis treatment after bone mineral density testing.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20010101

• Estradiol regulates monocyte chemotactic protein-1 in human coronary artery smooth muscle cells: a mechanism for its antiatherogenic effect.

  Menopause (New York, N.Y.) 20010101

• From adjuvant therapy to breast cancer prevention: BCPT and STAR.

  The breast journal 20010101

• Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.

  Cancer investigation 20010101

• American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20010101

• Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen.

  Menopause (New York, N.Y.) 20010101

• Vertebral fractures: a hidden problem of osteoporosis.

  Medical science monitor : international medical journal of experimental and clinical research 20010101

• Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator.

  Toxicologic pathology 20010101

• Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation.

  Reviews in endocrine & metabolic disorders 20010101

• The impact of risk on preference values: implications for evaluations of postmenopausal osteoporosis therapy.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20010101

• Preventive effects of raloxifene and melatonin in N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats.

  Neoplasma 20010101

• [New molecules].

  Journal de pharmacie de Belgique 20010101

• Raloxifene and endometrial cancer.

  Tumori 20010101

• New strategies for the treatment of breast cancer.

  Breast cancer (Tokyo, Japan) 20010101

• Proliferative lesions of ovarian granulosa cells and reversible hormonal changes induced in rats by a selective estrogen receptor modulator.

  Toxicologic pathology 20010101

• Selective estrogen receptor modulators: mechanism of action and clinical experience. Focus on raloxifene.

  Reproduction, fertility, and development 20010101

• Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.

  Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20010101

• [Antiestrogens: mechanism of action and clinical applications].

  Salud publica de Mexico 20010101

• Raloxifene: another selective estrogen modulator.

  In vivo (Athens, Greece) 20010101

• Cancer prevention and early detection.

  Clinical journal of oncology nursing 20010101

• Chemoprevention for high-risk women: tamoxifen and beyond.

  The breast journal 20010101

• [Patients with fractures are in the front line for osteoporosis treatment but how to treat?].

  Duodecim; laaketieteellinen aikakauskirja 20010101

• Raloxifene and prevention of vertebral fracture (cont'd): mainly when oestrogen is contraindicated.

  Prescrire international 20001201

• Raloxifene: results from the MORE study.

  Journal of musculoskeletal & neuronal interactions 20001201

• Raloxifene: a review of its use in postmenopausal osteoporosis.

  Drugs 20000801

• The effect of raloxifene on coronary arteries in aged ovariectomized ewes.

  Journal of veterinary pharmacology and therapeutics 20000601

• [Raloxifene (Celvista, Evista)].

  Revue medicale de Bruxelles 20000201

• Estrogen synthesis in human colon cancer epithelial cells.

  The Journal of steroid biochemistry and molecular biology 19991231

• Comparative analyses of mechanistic differences among antiestrogens.

  Endocrinology 19991201

• The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

  JAMA 19990616

• Clinical effects of raloxifene hydrochloride in women.

  Annals of internal medicine 19990302

• Tamoxifen for prevention of breast cancer.

  The Medical letter on drugs and therapeutics 19990101

• An estrogen receptor basis for raloxifene action in bone.

  The Journal of steroid biochemistry and molecular biology 19990101

• Raloxifene-associated hepatitis.

  Lancet (London, England) 19981107

• Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.

  Endocrinology 19981001

• Raloxifene.

  Drugs & aging 19980401

• Superinduction of c-fos gene expression by estrogen in cultured guinea-pig endometrial cells requires priming by a cycloheximide-dependent mechanism.

  Endocrinology 19920901

• Ligand dissociation from estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations.

  Molecular endocrinology (Baltimore, Md.)